<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Atheroscler Thromb</journal-id><journal-id journal-id-type="iso-abbrev">J Atheroscler Thromb</journal-id><journal-id journal-id-type="pmc-domain-id">3110</journal-id><journal-id journal-id-type="pmc-domain">japanaththr</journal-id><journal-id journal-id-type="publisher-id">jat</journal-id><journal-title-group><journal-title>Journal of Atherosclerosis and Thrombosis</journal-title></journal-title-group><issn pub-type="ppub">1340-3478</issn><issn pub-type="epub">1880-3873</issn><issn-l>1340-3478</issn-l><publisher><publisher-name>Japan Atherosclerosis Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11537794</article-id><article-id pub-id-type="pmcid-ver">PMC11537794.1</article-id><article-id pub-id-type="pmcaid">11537794</article-id><article-id pub-id-type="pmcaiid">11537794</article-id><article-id pub-id-type="pmid">39168622</article-id><article-id pub-id-type="doi">10.5551/jat.RV22025</article-id><article-id pub-id-type="publisher-id">DN/JST.JSTAGE/jat/RV22025</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Fibroblast Growth Factors in Cardiovascular Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Morita</surname><given-names initials="H">Hideaki</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hoshiga</surname><given-names initials="M">Masaaki</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><aff id="aff1"><label>1</label>Department of Cardiology, Osaka Medical and Pharmaceutical University, Osaka, Japan</aff></contrib-group><author-notes><corresp id="c1">Address for correspondence:Hideaki Morita, Department of Cardiology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-machi Takatsuki, Osaka, 569-8686 Japan
E-mail: <email>hideaki.morita@ompu.ac.jp </email></corresp></author-notes><pub-date pub-type="ppub"><day>1</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>22</day><month>8</month><year>2024</year></pub-date><volume>31</volume><issue>11</issue><issue-id pub-id-type="pmc-issue-id">474443</issue-id><fpage>1496</fpage><lpage>1511</lpage><history><date date-type="accepted"><day>3</day><month>7</month><year>2024</year></date><date date-type="received"><day>1</day><month>7</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>11</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>06</day><month>11</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-11-06 16:25:17.470"><day>06</day><month>11</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>2024 Japan Atherosclerosis Society</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncsalicense">https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-sa/4.0/">http://creativecommons.org/licenses/by-nc-sa/4.0/</ext-link></license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jat-31-1496.pdf"/><abstract specific-use="secondary-disallow"><p>Despite advancements in managing traditional cardiovascular risk factors, many cardiovascular diseases (CVDs) persist. Fibroblast growth factors (FGFs) have emerged as potential diagnostic markers and therapeutic targets for CVDs. FGF1, FGF2, and FGF4 are primarily used for therapeutic angiogenesis. Clinical applications are being explored based on animal studies using approaches such as recombinant protein administration and adenovirus-mediated gene delivery, targeting patients with coronary artery disease and lower extremity arterial disease. Although promising results have been observed in animal models and early-stage clinical trials, further studies are required to assess their therapeutic potential. The FGF19 subfamily, consisting of FGF19, FGF21, and FGF23, act via endocrine signaling in various organs. FGF19, primarily expressed in the small intestine, plays important roles in glucose, lipid, and bile acid metabolism and has therapeutic potential for metabolic disorders. FGF21, found in various tissues, improves glucose metabolism and insulin sensitivity, suggesting potential for treating obesity and diabetes. FGF23, primarily secreted by osteocytes, regulates vitamin D and phosphate metabolism and serves as an important biomarker for chronic kidney disease and CVDs. Thus, FGFs holds promise for both therapeutic and diagnostic applications in metabolic and cardiovascular diseases. Understanding the mechanisms of FGF may pave the way for novel strategies to prevent and manage CVDs, potentially addressing the limitations of current treatments. This review explores the roles of FGF1, FGF2, FGF4, and the FGF19 subfamily in maintaining cardiovascular health. Further research and clinical trials are crucial to fully understand the therapeutic potential of FGFs in managing cardiovascular health.</p></abstract><kwd-group kwd-group-type="author"><kwd>Fibroblast growth factors</kwd><kwd>Cardiovascular disease</kwd><kwd>Atherosoclerosis</kwd><kwd>Cardiometabolic regulation</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="X1"><title>Introduction</title><p>
Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide. In 2019, CVDs were responsible for an estimated 18.6 million deaths, accounting for 32% of all global deaths<sup>
<xref rid="X19" ref-type="bibr">1)</xref>
</sup>. Major risk factors for CVDs include dyslipidemia, hypertension, diabetes mellitus, obesity, and smoking. Among these risk factors, low-density lipoprotein cholesterol (LDL-C) has emerged as a suitable target for the treatment and prevention of CVDs. Numerous lipid-lowering drugs have been developed for clinical use, with statins playing a major role in the primary and secondary prevention of CVDs. Statin administration has been shown to reduce the prevalence of cardiovascular events by 30&#8211;40%. However, despite their efficacy, a substantial number of cardiovascular events remain unprevented, thereby imposing a substantial burden on healthcare systems worldwide.
</p><p>
Recently, fibroblast growth factors (FGFs) have emerged as promising novel molecules with potential involvement in cardiovascular development and homeostasis. The human FGF family comprises 22 members, including 18 secreted signaling proteins and four intracellular proteins. Secreted FGFs bind to and activate the cell surface tyrosine kinase FGF receptors (FGFRs) that are encoded by four genes (<italic toggle="yes">FGFR1&#8211;4</italic>)<sup>
<xref rid="X20" ref-type="bibr">2)</xref>
</sup>. In contrast, intracellular FGFs act as cofactors for voltage-gated sodium channels and other molecules<sup>
<xref rid="X21" ref-type="bibr">3)</xref>
</sup>. The FGF family plays crucial roles in maintaining cardiovascular health and exerts its influence during embryonic development, organogenesis, cell growth and survival, angiogenesis, tissue repair and regeneration, metabolic function, and homeostasis maintenance.
</p><p>The present review aims to highlight the potential of FGFs, specifically FGF1, FGF2, FGF4, and the FGF19 subfamily, as markers for cardiovascular risk assessment and therapeutic targets for CVD treatment. By exploring the intricate roles of FGFs in cardiovascular health and disease, we may pave the way for novel strategies in CVD prevention and management, ultimately addressing the substantial burden that remains despite current therapies.</p><sec id="X2"><title>Structure and Classification of FGF Family</title><p>
The FGF family comprises structurally related growth factors that exert various biological effects by interacting with specific cell surface receptors. The FGF family includes 22 members, divided into seven subfamilies based on sequence homology and receptor specificity <bold>
(
<xref rid="X3" ref-type="fig">Fig.1</xref>
)
</bold><sup>
<xref rid="X21" ref-type="bibr">3)</xref>
</sup>. Canonical FGFs are characterized by their conserved core domain of approximately 140 amino acids, essential for receptor binding<sup>
<xref rid="X22" ref-type="bibr">4)</xref>
</sup>. Variations within the FGF family arise from differences in their receptor-binding specificity, leading to distinct physiological roles in various tissues and organ systems.
</p><fig position="float" id="X3" orientation="portrait"><label>Fig.1. Classification of fibroblast growth factors (FGFs)</label><caption><p>The figure illustrates the classification of the fibroblast growth factor (FGF) family into three main functional groups: paracrine FGFs, endocrine FGFs and intracellular FGFs.</p><p>Paracrine FGFs (Yellow): These FGFs function primarily through local cell signaling and are categorized into five subfamilies: FGF1 subfamily includes FGF1 and FGF2; FGF4 subfamily includes FGF4, FGF5, and FGF6; FGF7 subfamily includes FGF3, FGF7, FGF10, and FGF22; FGF8 subfamily includes FGF8, FGF17, and FGF18; FGF9 subfamily includes FGF9, FGF16, and FGF20.</p><p>Endocrine FGFs (Red): These FGFs are involved in systemic signaling and are part of the FGF19 subfamily. This function group includes FGF19, FGF21, and FGF23.</p><p>Intracellular FGFs (Blue): These FGFs function within the cell and are part of FGF11 subfamily. This functional group includes FGF11, FGF12, FGF13, and FGF14.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="31_RV22025_1.jpg"/></fig><p>
FGFs exert their biological effects by binding to a family of high-affinity cell surface receptors known as FGFRs. The FGFR family comprises four members (FGFR1&#8211;4) with distinct tissue distributions and specificities for different FGF ligands<sup>
<xref rid="X21" ref-type="bibr">3)</xref>
</sup>. FGF binding induces FGFR dimerization and autophosphorylation of intracellular tyrosine residues, initiating downstream signaling cascades<sup>
<xref rid="X23" ref-type="bibr">5)</xref>
</sup>.
</p><p>
The major intracellular signaling pathways activated by FGFRs include mitogen-activated protein kinase, phosphoinositide 3-kinase/protein kinase B (PI3K/AKT), and signal transducer and activator of transcription pathways<sup>
<xref rid="X22" ref-type="bibr">4)</xref>
</sup>. These pathways regulate diverse cellular processes, such as proliferation, differentiation, survival, and migration, making FGF signaling critical for embryonic development and tissue homeostasis <bold>
(
<xref rid="X4" ref-type="table">Table 1</xref>
)
</bold><sup>
<xref rid="X24" ref-type="bibr">6</xref>
-
<xref rid="X25" ref-type="bibr">19)</xref>
</sup>.
</p><table-wrap position="float" id="X4" orientation="portrait"><label>Table 1.</label><caption><title>Classification and physiological effects of FGF family</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1" width="12%"/><col span="1" width="11%"/><col span="1" width="10%"/><col span="1" width="11%"/><col span="1" width="17%"/><col span="1" width="34%"/><col span="1" width="5%"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">FGF sub family</th><th colspan="1" rowspan="1"/><th align="center" colspan="1" rowspan="1">FGF</th><th align="center" colspan="1" rowspan="1">Cofactor</th><th align="center" colspan="1" rowspan="1">Receptor specificity</th><th align="center" colspan="1" rowspan="1">Physiological role</th><th align="center" colspan="1" rowspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" colspan="1" rowspan="2">FGF1 sub family</td><td align="left" colspan="1" rowspan="15">Paracrine FGFs</td><td align="left" colspan="1" rowspan="1">FGF1 (aFGF)</td><td align="left" colspan="1" rowspan="15">heparin, heparin sulfate</td><td align="left" colspan="1" rowspan="1">All FGFRs</td><td align="left" colspan="1" rowspan="2">cellular proliferation, survival, metabolism, morphogenesis, differentiation, embryonic development, angiogenesis, tissue repair, and regeneration</td><td align="center" colspan="1" rowspan="2">6</td></tr><tr><td align="left" colspan="1" rowspan="1">FGF2 (bFGF)</td><td align="left" colspan="1" rowspan="1">FGFR 1c, 3c &gt; 2c, 1b, 4</td></tr><tr><td align="center" colspan="1" rowspan="3">FGF4 sub family</td><td align="left" colspan="1" rowspan="1">FGF4</td><td colspan="1" rowspan="3">FGFR 1c, 2c &gt; 3c, 4</td><td align="left" colspan="1" rowspan="1">Cardiac valve leaflet formation, Limb development</td><td align="center" colspan="1" rowspan="1">7</td></tr><tr><td align="left" colspan="1" rowspan="1">FGF5</td><td align="left" colspan="1" rowspan="1">Hair growth</td><td align="center" colspan="1" rowspan="1">8</td></tr><tr><td align="left" colspan="1" rowspan="1">FGF6</td><td align="left" colspan="1" rowspan="1">Myogenesis</td><td align="center" colspan="1" rowspan="1">9</td></tr><tr><td align="center" colspan="1" rowspan="4">FGF7 sub family</td><td align="left" colspan="1" rowspan="1">FGF3</td><td align="left" colspan="1" rowspan="4">FGFR 2b &gt; 1b</td><td align="left" colspan="1" rowspan="1">Inner ear development</td><td align="center" colspan="1" rowspan="1">10</td></tr><tr><td align="left" colspan="1" rowspan="1">FGF7 (KGF)</td><td align="left" colspan="1" rowspan="1">Branching morphogenesis</td><td align="center" colspan="1" rowspan="1">11</td></tr><tr><td align="left" colspan="1" rowspan="1">FGF10</td><td align="left" colspan="1" rowspan="1">Branching morphogenesis</td><td align="center" colspan="1" rowspan="1">12</td></tr><tr><td align="left" colspan="1" rowspan="1">FGF22</td><td align="left" colspan="1" rowspan="1">Presynaptic neural organizer</td><td align="center" colspan="1" rowspan="1">13</td></tr><tr><td align="center" colspan="1" rowspan="3">FGF8 sub family</td><td align="left" colspan="1" rowspan="1">FGF8</td><td align="left" colspan="1" rowspan="3">FGFR 3c &gt; 4 &gt; 2c &gt; 1c &gt;&gt;3b</td><td align="left" colspan="1" rowspan="1">Brain, eye, ear and limb development</td><td align="center" colspan="1" rowspan="1">14</td></tr><tr><td align="left" colspan="1" rowspan="1">FGF17</td><td align="left" colspan="1" rowspan="1">Cerebral and cerebellar development</td><td align="center" colspan="1" rowspan="1">15</td></tr><tr><td align="left" colspan="1" rowspan="1">FGF18</td><td align="left" colspan="1" rowspan="1">Bone development</td><td align="center" colspan="1" rowspan="1">16</td></tr><tr><td align="center" colspan="1" rowspan="3">FGF9 sub family</td><td align="left" colspan="1" rowspan="1">FGF9</td><td align="left" colspan="1" rowspan="3">FGFR 3c &gt; 2c &gt; 1c, 3b &gt;&gt; 4</td><td align="left" colspan="1" rowspan="1">Gonadal development, Organogenesis</td><td align="center" colspan="1" rowspan="1">17</td></tr><tr><td align="left" colspan="1" rowspan="1">FGF16</td><td align="left" colspan="1" rowspan="1">Heart development</td><td align="center" colspan="1" rowspan="1">18</td></tr><tr><td align="left" colspan="1" rowspan="1">FGF20</td><td align="left" colspan="1" rowspan="1">Neurotrophic factor</td><td align="center" colspan="1" rowspan="1">19</td></tr><tr><td align="center" colspan="1" rowspan="3">FGF19 sub family</td><td align="left" colspan="1" rowspan="3">Endocrine FGFs</td><td align="left" colspan="1" rowspan="1">FGF19/15</td><td align="left" colspan="1" rowspan="2">&#946;Klotho</td><td align="left" colspan="1" rowspan="3">FGFR 1c, 2c, 3c, 4</td><td align="left" colspan="1" rowspan="1">Bile acid homeostasis, Lipolysis, Gall bladder filling</td><td align="center" colspan="1" rowspan="1">42, 43</td></tr><tr><td align="left" colspan="1" rowspan="1">FGF21</td><td align="left" colspan="1" rowspan="1">Fasting response, Glucose homeostasis, Lipolysis and Lipogogenesis</td><td align="center" colspan="1" rowspan="1">54-57</td></tr><tr><td align="left" colspan="1" rowspan="1">FGF23</td><td align="left" colspan="1" rowspan="1">&#945;Klotho</td><td align="left" colspan="1" rowspan="1">Phosphate homeostasis, Vitamin D homeostasis</td><td align="center" colspan="1" rowspan="1">72-77</td></tr><tr><td align="center" colspan="1" rowspan="4">FGF11 sub family</td><td align="left" colspan="1" rowspan="4">Intracellular FGFs</td><td align="left" colspan="1" rowspan="1">FGF11</td><td align="left" colspan="1" rowspan="1">none??</td><td align="left" colspan="1" rowspan="1">no known activity</td><td align="left" colspan="1" rowspan="1">not established</td><td colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="5" rowspan="1">FGF12</td></tr><tr><td align="left" colspan="5" rowspan="1">FGF13</td></tr><tr><td align="left" colspan="5" rowspan="1">FGF14</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>The FGF family consists of a variety of proteins that serve multiple biological functions. These proteins are essential for processes, such as cell growth, differentiation, migration, and tissue repair and regeneration. Similar to other growth factors, FGFs bind to specific cell surface receptors, known as FGF receptors (FGFR1&#8211;4)</p></fn></table-wrap-foot></table-wrap></sec><sec id="X5"><title>FGF1</title><p>
FGF, isolated from the brain and pituitary extracts, was found to be involved in fibroblast proliferation, as revealed by bioassays<sup>
<xref rid="X26" ref-type="bibr">20</xref>
,
<xref rid="X27" ref-type="bibr">21)</xref>
</sup>. Furthermore, when the same extracts were fractionated, acidic FGF (FGF1) and basic FGF (FGF2) were obtained. FGF1 regulates and enhances the angiogenesis by triggering the migration, proliferation, and differentiation of endothelial cells<sup>
<xref rid="X28" ref-type="bibr">22)</xref>
</sup>, ultimately leading to the development of new capillaries from existing vessels.
</p><p>
Following successful experimental studies, the effectiveness of the combined therapy with coronary artery bypass grafting and FGF1 has been reported in clinical practice. In a study involving 20 patients with three-vessel coronary artery disease, intramyocardial injection of FGF1 near the left anterior descending coronary artery during coronary artery bypass surgery improved collateral circulation and capillary proliferation<sup>
<xref rid="X29" ref-type="bibr">23)</xref>
</sup>. Additionally, the FGF1-treated group exhibited increased blood flow compared to the control group, along with improved cardiac function and New York Heart Association classification after three years of follow-up<sup>
<xref rid="X30" ref-type="bibr">24)</xref>
</sup>. Furthermore, the positive effects of FGF1 on peripheral blood flow have been demonstrated in clinical trials. In a phase I open-label trial, intramuscular injection of naked plasmid DNA encoding FGF1 (NV1FGF) into the lower leg improved perfusion in 51 patients with critical lower extremity arterial disease (LEAD)<sup>
<xref rid="X31" ref-type="bibr">25)</xref>
</sup>. A subsequent, a phase II double-blind, randomized, placebo-controlled trial revealed that intramuscular injections of NV1FGF in 125 patients with LEAD, presenting with a non-healing ulcer and who were unsuitable for revascularization, led to a 50% reduction in amputation rates and a trend toward reduced mortality<sup>
<xref rid="X32" ref-type="bibr">26)</xref>
</sup>. However, the TAMARIS trial, a large-scale, placebo-controlled, randomized phase III trial involving 525 patients with critical limb ischemia from 171 sites across 30 countries, provided no evidence that neovascularization therapy using NV1FGF was effective in reducing lower leg amputations or death<sup>
<xref rid="X33" ref-type="bibr">27)</xref>
</sup>.
</p></sec><sec id="X6"><title>FGF2</title><p>
The angiogenic effects of FGF2 are also widely recognized. FGF2 promotes the migration and growth of endothelial cells <italic toggle="yes">in vivo</italic><sup>
<xref rid="X34" ref-type="bibr">28)</xref>
</sup>. It also stimulates mitogenesis of smooth muscle cells and fibroblasts, contributing to the development of collateral vessels<sup>
<xref rid="X35" ref-type="bibr">29)</xref>
</sup>. In a phase I, randomized, dose-escalation trial involving 25 patients with coronary artery disease and stable angina, the administration of FGF2 reduced the ischemic area in the myocardium, improved exercise performance, and decreased angina frequency<sup>
<xref rid="X36" ref-type="bibr">30)</xref>
</sup>. Subsequently, the FGF Initiating RevaScularization Trial (FIRST) was conducted on 337 patients with coronary artery disease to further evaluate the efficacy and safety of recombinant FGF2. The FIRST, a multicenter, randomized, double-blind, placebo-controlled trial of demonstrated that single intracoronary infusion of FGF2, led to beneficial effects in the initial months; however, these effects were not sustained<sup>
<xref rid="X37" ref-type="bibr">31)</xref>
</sup>. In a randomized, double-blind, placebo-controlled study, surgical delivery of heparin beads with absorbed FGF2, implanted into ischemic and viable but ungraftable myocardial regions in 24 patients, reduced ischemic size and angina symptoms for three years<sup>
<xref rid="X38" ref-type="bibr">32)</xref>
</sup>. Additionally, a double-blind, placebo-controlled, dose-escalation trial conducted on 19 patients with LEAD demonstrated that patients who received arterial FGF2 exhibited improved calf blood flow compared to those who received a placebo<sup>
<xref rid="X39" ref-type="bibr">33)</xref>
</sup>. The therapeutic angiogenesis with recombinant FGF2 for intermittent claudication (TRAFFIC) trial investigated the effects of intra-arterial recombinant FGF2 on the exercise capacity of patients with intermittent claudication. In this randomized trial, 190 patients received either a placebo, a single dose, or a double dose of recombinant FGF2 (rFGF2). The primary outcome was the change in the peak walking time at 90 days. The single-dose group showed a significant improvement compared to the placebo group, but the double-dose group did not exhibit any additional benefit. The safety profiles were similar across all groups, supporting the potential of rFGF2 in therapeutic angiogenesis<sup>
<xref rid="X40" ref-type="bibr">34)</xref>
</sup>. Overall, angiogenic therapies using FGF2 have shown promising results in both basic research and clinical trials, and FGF2 is expected to play a crucial role in the treatment of various diseases.
</p></sec><sec id="X7"><title>FGF4</title><p>
FGF4, a 206-amino-acid protein initially isolated from a human gastric tumor, shares approximately 40% homology with FGF1 and FGF2 <sup>
<xref rid="X41" ref-type="bibr">35)</xref>
</sup>. Although FGF2 has primarily been studied using recombinant protein preparations, FGF4&#8217;s robust effects, stability, targeted delivery, promising clinical outcomes, and favorable safety profiles have made it a suitable candidate for gene therapy applications. The AGENT trial evaluated the efficacy and safety of angiogenic gene therapy using Ad5-FGF4 (a serotype 5 adenovirus encoding FGF4) in 79 patients with stable chronic angina<sup>
<xref rid="X42" ref-type="bibr">36)</xref>
</sup>. Overall, the trial did not find a significant difference in exercise time between the treatment and placebo groups. However, a post hoc analysis excluding patients with a baseline exercise time exceeding 10 min revealed a significant improvement in exercise capacity in the treated group compared to that in the placebo group at both 4 and 12 weeks. Follow-up trials (AGENT-2, AGENT-3, and AGENT-4) conducted to explore the safety and efficacy of this therapy did not show significant overall benefits from the treatments itself<sup>
<xref rid="X43" ref-type="bibr">37</xref>
,
<xref rid="X44" ref-type="bibr">38)</xref>
</sup>. However, a subsequent analysis suggested a potential sex-specific benefit, with women appearing to respond more favorably.
</p><p>
An ongoing phase III open-label trial, ASPIRE, is assessing the efficacy of intracoronary adenoviral FGF4 compared to standard care using myocardial perfusion imaging in 100 patients with coronary artery disease<sup>
<xref rid="X45" ref-type="bibr">39)</xref>
</sup>. Additionally, the AWARE phase III, randomized, double-blind, placebo-controlled trial is planned to evaluate the safety and efficacy of intracoronary adenoviral FGF4 delivery, specifically in women with stable angina pectoris.
</p><p>The AFFIRM study, a phase III clinical trial, is also ongoing to determine whether a single intracoronary infusion of Ad5-FGF4 is effective in improving angina-limited exercise duration, angina functional class, frequency of angina attacks, frequency of nitroglycerin usage, and quality of life in patients with refractory angina.</p><p>
The optimal strategy for administering angiogenic growth factors to stimulate therapeutic angiogenesis is also crucial. Intravenous, intracoronary, and intramyocardial routes of administration have been explored. Controlled and sustained delivery of angiogenic factors is critical for achieving stable and functional neovascularization, as the process of tissue regeneration and angiogenesis takes weeks or months<sup>
<xref rid="X46" ref-type="bibr">40)</xref>
</sup>.
</p></sec><sec id="X8"><title>FGF19 Subfamily</title><sec id="X9"><title>FGF19</title><p>
FGF19 was initially identified in the human brain during embryonic and fetal development in 1999. Its rodent counterpart, FGF15, is found in the central nervous system and promotes neuronal maturation. Numerous animal studies have validated the therapeutic potential of FGF19 in the managing metabolic disorders, such as obesity and diabetes<sup>
<xref rid="X47" ref-type="bibr">41)</xref>
</sup>.
</p><p>
FGF19 plays an important role in various metabolic processes, including the regulation of glucose, lipid, and bile acid metabolism, as well as gall bladder relaxation and filling. FGF19 is highly expressed in the small intestine and is secreted into the enterohepatic circulation postprandially, stimulated by bile acids through the activation of the farnesoid X receptor (FXR). It acts on the FGFR/&#946;Klotho complex expressed in the liver<sup>
<xref rid="X48" ref-type="bibr">42)</xref>
</sup>. FGF19 negatively regulates bile acid synthesis by suppressing the expression of CYP7A1, a key enzyme in bile acid synthesis. The expression of FGF19 is regulated by the nuclear receptor FXR, a ligand for bile acids<sup>
<xref rid="X49" ref-type="bibr">43)</xref>
</sup>. Bile acids are secreted into the intestine during feeding and play crucial roles in the absorption of lipid components. Similarly, the expression of FGF19 increases during feeding and has been reported to regulate hepatic refeeding responses, including the inhibition of gluconeogenesis and the promotion of glycogen and protein synthesis <bold>
(
<xref rid="X10" ref-type="fig">Fig.2</xref>
)
</bold><sup>
<xref rid="X50" ref-type="bibr">44)</xref>
</sup>. Bile acids play a crucial role in cholesterol excretion, helping to regulate the body&#8217;s cholesterol balance and prevent excessive accumulation of cholesterol. Therefore, bile acids are critical in cholesterol metabolism and contribute to the prevention of CVDs.
</p><fig position="float" id="X10" orientation="portrait"><label>Fig.2. Regulation and effects of FGF19</label><caption><p>FGF19 is primarily synthesized and secreted by the small intestine in response to bile acid stimulation. Bile acids in the intestine activates the farnesoid X receptor (FXR), inducing the expression of FGF19.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="31_RV22025_2.jpg"/></fig><p>
In an experimental study, NGM282, an engineered FGF19 analog, enhanced high-density lipoprotein (HDL) formation and cholesterol removal from the liver by modulating LXR signaling through ABCA1 and FGFR4 <sup>
<xref rid="X51" ref-type="bibr">45)</xref>
</sup>. The study also demonstrated that the administration of an HMG-CoA reductase inhibitor or an antibody against proprotein convertase subtilisin/kexin type 9 eliminated the increase in total cholesterol, HDL cholesterol (HDL-C), and LDL-C caused by FGF19 in <italic toggle="yes">db/db</italic> mice. Additionally, in Apoe-/- mice on a Western diet, NGM282 treatment significantly decreased atherosclerotic lesions in the aorta. In a study involving 1,166 Chinese patients with coronary artery disease, the combined measurement of cardiometabolic biomarkers, including adipocyte fatty acid-binding protein, lipocalin-2, and FGF19, along with conventional risk factors improved the prediction of cardiovascular events in patients with stable coronary artery disease<sup>
<xref rid="X52" ref-type="bibr">46)</xref>
</sup>. Rats with streptozotocin-induced diabetes demonstrated reduced serum FGF19 levels and lower FGF19 protein expression compared to control rats. Recombinant FGF19 administration via intraperitoneal injection in these rats decreased plasma glucose, plasma total cholesterol, plasma LDL-C, and serum malondialdehyde levels while increasing serum adiponectin and plasma HDL-C levels compared to that in control rats. Furthermore, FGF19 administration increased the protein levels of the glucose transporter GLUT4 and pyruvate dehydrogenase E1-alpha compared to those in control rats, suggesting that FGF19 improves energy metabolism by increasing glucose uptake and decreasing lipid levels<sup>
<xref rid="X53" ref-type="bibr">47)</xref>
</sup>.
</p><p>
The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing in Western countries<sup>
<xref rid="X54" ref-type="bibr">48)</xref>
</sup>. Patients with NAFLD not only face an increased risk of non-alcoholic steatohepatitis (NASH), but also often have comorbidities, such as obesity, diabetes mellitus, hypertension, and dyslipidemia, all of which heighten their CVD risk. FGF19 regulates bile acid metabolism and exerts insulin-like effects on glycogen synthesis and gluconeogenesis, potentially impacting multiple pathways involved in NASH development.
</p><p>
A multicenter, randomized, double-blind, placebo-controlled phase II showed that NGM282 administration significantly reduced fat content in patients without causing severe adverse events<sup>
<xref rid="X55" ref-type="bibr">49)</xref>
</sup>. However, a subsequent randomized, double-blind, placebo-controlled phase IIb study with a larger cohort showed positive effects on many secondary endpoints but did not demonstrate improvement in liver fibrosis, the primary endpoint<sup>
<xref rid="X56" ref-type="bibr">50)</xref>
</sup>. Consequently, the program was terminated.
</p><p>
Recent studies suggest that a communication exists between the gut and myocardium, potentially regulating cardiac hypertrophy<sup>
<xref rid="X57" ref-type="bibr">51)</xref>
</sup>. The gut and heart have been shown to communicate through incretins produced by the gut after meals, as well as bile acids. Both incretins and bile acids target the myocardium and affect the cardiac function<sup>
<xref rid="X58" ref-type="bibr">52)</xref>
</sup>. In a clinical study, circulating levels of FGF19 in patients with heart failure were significantly elevated compared to those in age-matched individuals without a history of CVDs. In a large cohort of 287 patients with heart failure, high FGF19 levels (HR=1.295, 95% CI: 1.035&#8211;1.619, <italic toggle="yes">p</italic>-value=0.024) were identified as independent predictors of all-cause mortality in Cox analysis<sup>
<xref rid="X59" ref-type="bibr">53)</xref>
</sup>. Furthermore, <italic toggle="yes">Fgf15</italic>-knockout mice did not develop cardiac hypertrophy in response to high-fat diet, isoproterenol, or cold exposure. <italic toggle="yes">In vitro</italic> studies further confirmed that FGF19 directly promotes cardiomyocyte hypertrophy, revealing an inter-organ signaling pathway from the gut to the heart via FGF15/19. This gut-&#8211;heart signaling pathway regulates cardiac hypertrophy and myocardial fatty acid metabolism<sup>
<xref rid="X59" ref-type="bibr">53)</xref>
</sup> and holds promise for developing innovative diagnostic and therapeutic strategies for heart failure.
</p></sec><sec id="X11"><title>FGF21</title><p>
FGF21, initially isolated from mouse embryo, is composed of 210 amino acids. In contrast, human FGF21 consists of 209 amino acids and shares 75% identity with mouse FGF21 <sup>
<xref rid="X60" ref-type="bibr">54)</xref>
</sup>. Recently, FGF21 has been reported to be highly expressed in adipose tissue as well as in the liver, pancreas, skeletal muscle, heart, kidneys, and testes<sup>
<xref rid="X61" ref-type="bibr">55)</xref>
</sup>.
</p><p>
Studies employing glucose uptake assays have demonstrated that human recombinant FGF21 stimulates glucose uptake in primary human adipocytes and differentiated mouse 3T3-L1 adipocytes<sup>
<xref rid="X61" ref-type="bibr">55)</xref>
</sup>. Unlike insulin, which activates glucose transporter-4 (GLUT-4), FGF21 primarily acts through GLUT-1 in adipocytes to regulate blood glucose levels. Administration of FGF-21 to obese rodents with diabetes and rhesus monkeys has been shown to improve abnormal glucose metabolism, body weight gain, and triglyceride metabolism<sup>
<xref rid="X61" ref-type="bibr">55</xref>
-
<xref rid="X64" ref-type="bibr">58)</xref>
</sup>. When FGF21 was administered to mice lacking either FGFR1 or &#946;Klotho, most of its effect on glucose metabolism and energy expenditure were lost<sup>
<xref rid="X65" ref-type="bibr">59</xref>
,
<xref rid="X66" ref-type="bibr">60)</xref>
</sup>. These findings indicate that direct action of FGF21 on adipocytes is crucial for metabolic regulation.
</p><p>
The pleiotropic actions of FGF21 result in several outcomes, including enhanced total-body insulin sensitivity<sup>
<xref rid="X67" ref-type="bibr">61)</xref>
</sup>, improved pancreatic beta-cell function<sup>
<xref rid="X63" ref-type="bibr">57)</xref>
</sup>, reduced glucagon secretion from the pancreas<sup>
<xref rid="X61" ref-type="bibr">55)</xref>
</sup>, decreased hepatic lipogenesis, and induction of energy expenditure through the activation of brown fat<sup>
<xref rid="X61" ref-type="bibr">55</xref>
,
<xref rid="X62" ref-type="bibr">56)</xref>
</sup>. The functions of both adipose tissue types are regulated by sympathetic nerve stimulation. Norepinephrine released from sympathetic nerve terminals promotes lipolysis, fatty acid oxidation, and thermogenesis in brown adipose tissue, and induces lipolysis in white adipose tissue. Additionally, the administration of FGF21 to mice or primary cultured cells has been shown to activate the sympathetic nervous system, promote fatty acid oxidation in brown adipocytes, and induce the formation of beige cells within white adipocytes<sup>
<xref rid="X68" ref-type="bibr">62)</xref>
</sup>. This suggests that FGF21 may promote energy expenditure and reduce body weight through its influence on brown adipose tissue and the induction of beige cells. FGFR1 is barely expressed in hepatocytes <italic toggle="yes">in vivo</italic>; therefore, it is unlikely that FGF21 acts directly on the liver<sup>
<xref rid="X69" ref-type="bibr">63)</xref>
</sup>. Administration of FGF21 to primary adipocytes increases the amount of adiponectin, which regulates the overall glucose and lipid balance through its endocrine effects on the liver and skeletal muscles. Furthermore, when FGF21 was administered to adiponectin-knockout mice, FGF21&#8217;s ability to improve glucose metabolism, lipid metabolism, and energy expenditure was diminished. This finding suggests that FGF21&#8217;s metabolic effects may be mediated indirectly through the release of adiponectin from adipose tissue <bold>
(
<xref rid="X12" ref-type="fig">Fig.3</xref>
)
</bold><sup>
<xref rid="X70" ref-type="bibr">64)</xref>
</sup>.
</p><fig position="float" id="X12" orientation="portrait"><label>Fig.3. Regulation and effects of FGF21</label><caption><p>FGF21 is primarily synthesized and secreted in response to fasting. Fatty acids activate peroxisome proliferator-activated receptors-&#945; (PPAR-&#945;) in the liver and peroxisome proliferator-activated receptors-&#947; (PPAR-&#947;) in the pancreas, inducing the expression of FGF21.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="31_RV22025_3.jpg"/></fig><p>
Recently, several animal studies have reported that FGF21 exerts cardioprotective effects against various stressors. When treated with isoproterenol, <italic toggle="yes">Fgf21</italic>-knockout mice exhibited enhanced eccentric hypertrophy, activation of pro-inflammatory pathways, and reduced fatty acid oxidation compared to control mice 65. These changes were already present in newborn <italic toggle="yes">Fgf21</italic>-knockout mice, and conversely, FGF21 treatment reversed these detrimental effects <italic toggle="yes">in vivo</italic> and in cultured cardiomyocytes<sup>
<xref rid="X71" ref-type="bibr">65)</xref>
</sup>. Furthermore, FGF21 administration attenuated angiotensin II-induced cardiac hypertrophy in mice, while <italic toggle="yes">Sirt1</italic>-knockout mice showed diminished beneficial effects of FGF21 in attenuating angiotensin II-induced hypertrophy<sup>
<xref rid="X72" ref-type="bibr">66)</xref>
</sup>. FGF21 released from the liver and adipose tissue during ischemia/reperfusion injury appears to plays a crucial role in protecting the myocardium. This protection is mediated through the FGFR1/&#946;Klotho&#8211;PI3K/AKT&#8211;BCL-XL/BCL-2-associated death signaling network<sup>
<xref rid="X73" ref-type="bibr">67)</xref>
</sup>. Similarly, FGF21 contributes to the improved outcomes following experimental myocardial infarction, partly through an adiponectin-dependent mechanism<sup>
<xref rid="X74" ref-type="bibr">68)</xref>
</sup>.
</p><p>
Recent findings from population studies must be validated in independent cohorts before FGF21 can be used as a biomarker in the clinical setting<sup>
<xref rid="X75" ref-type="bibr">69)</xref>
</sup>. Two recent clinical trials have reported the promising effects of FGF21 analogs in improving the cardiometabolic profiles of patients with obesity and type 2 diabetes<sup>
<xref rid="X76" ref-type="bibr">70</xref>
,
<xref rid="X77" ref-type="bibr">71)</xref>
</sup>. These findings support the potential use of FGF21 as a therapeutic target for atherosclerosis and CVDs.
</p></sec><sec id="X13"><title>FGF23</title><p>
FGF23, a hormone, primarily secreted by osteoblasts and osteocytes, plays a crucial role in regulating phosphate metabolism and vitamin D homeostasis. It achieves this by suppressing renal tubular reabsorption of phosphate through interactions with FGFR1&#8211;4 and its co-receptor &#945;Klotho<sup>
<xref rid="X78" ref-type="bibr">72</xref>
-
<xref rid="X79" ref-type="bibr">74)</xref>
</sup>. The primary function of FGF23 is to downregulate the expression of the sodium phosphate cotransporters NaPi-2a and NaPi-2c in renal proximal tubules<sup>
<xref rid="X80" ref-type="bibr">75</xref>
-
<xref rid="X81" ref-type="bibr">77)</xref>
</sup>. FGF23 acts as a phosphaturic hormone, increasing the excretion of excess phosphate in urine and effectively regulating blood phosphate levels. FGF23 also decreases the level of 1,25-dihydroxy vitamin D [1,25-(OH)<sub>2</sub>D] and increases the level of parathyroid hormone (PTH). This regulation influences gastrointestinal calcium/phosphate absorption and renal phosphate reabsorption<sup>
<xref rid="X80" ref-type="bibr">75)</xref>
</sup>. Studies have shown that in chronic kidney disease (CKD), as kidney function declines, FGF23 levels rise early in the disease course, preceding increases in PTH levels and abnormalities in serum phosphorus and calcium concentrations<sup>
<xref rid="X82" ref-type="bibr">78)</xref>
</sup>. The progression typically involves an initial increase in serum FGF23 and decrease in serum &#945;Klotho concentration, followed by reductions in 1,25-(OH)<sub>2</sub>D levels, increases in serum PTH levels, and ultimately, elevated serum phosphate levels and decreased serum calcium levels in advanced CKD<sup>
<xref rid="X83" ref-type="bibr">79)</xref>
</sup>.
</p><p>
High circulating FGF23 levels are associated with increased mortality in patients undergoing hemodialysis<sup>
<xref rid="X84" ref-type="bibr">80)</xref>
</sup> and those with CKD<sup>
<xref rid="X85" ref-type="bibr">81)</xref>
</sup>, independent of serum phosphate levels and other traditional risk factors. Furthermore, in the Cardiovascular Health Study, high FGF23 levels were linked to all-cause mortality and incident heart failure in the general population<sup>
<xref rid="X86" ref-type="bibr">82)</xref>
</sup>. Additionally, elevated FGF23 levels were positively associated with all-cause mortality in both patients with CKD and the general population<sup>
<xref rid="X87" ref-type="bibr">83</xref>
,
<xref rid="X88" ref-type="bibr">84)</xref>
</sup>.
</p><p>
FGF23 has emerged as a useful biomarker in patients with heart failure. Elevated FGF23 levels have been associated with worsening heart failure, increased hospitalizations, and mortality in patients, both in chronic and acute heart failure settings<sup>
<xref rid="X89" ref-type="bibr">85</xref>
,
<xref rid="X90" ref-type="bibr">86)</xref>
</sup>. Patients with acute heart failure exhibited increased plasma FGF23 levels compared to controls; however, myocardial <italic toggle="yes">FGF23</italic> gene expression remained similar<sup>
<xref rid="X91" ref-type="bibr">87)</xref>
</sup>. There is still a limited understanding of the specific production site of FGF23, the mechanisms underlying the elevation of FGF23 levels during decompensated heart failure episodes, and its effects on kidney function. Nonetheless, FGF23 shows promise for use in risk stratification and developing treatment guidelines for heart failure.
</p><p>
Previous studies have reported that high serum concentrations of FGF23 are associated with left ventricular hypertrophy (LVH) in both experimental models<sup>
<xref rid="X78" ref-type="bibr">72)</xref>
</sup> and patients, particularly those CKD<sup>
<xref rid="X92" ref-type="bibr">88</xref>
-
<xref rid="X93" ref-type="bibr">92)</xref>
</sup>. Several hypotheses have been proposed regarding the development of LVH via FGF23 signaling. Grabner <italic toggle="yes">et al.</italic> showed that FGF23 directly induced LVH through FGFR4 activation and subsequent calcineurin/nuclear factor of activated T cells signaling, independent of its co-receptor &#945;Klotho<sup>
<xref rid="X78" ref-type="bibr">72</xref>
,
<xref rid="X94" ref-type="bibr">93)</xref>
</sup>. A specific FGFR4 antibody was found to inhibit FGF23-induced hypertrophy in isolated cardiac myocytes and attenuate LVH in rats with CKD<sup>
<xref rid="X82" ref-type="bibr">78)</xref>
</sup>. Thus, FGF23/FGFR4 pathway may be a potential therapeutic target for the treatment or prevention of LVH. In contrast, Andrukhova <italic toggle="yes">et al.</italic> demonstrated that FGF23 induced distal tubular sodium retention in an &#945;Klotho-dependent manner, leading to an increase in blood volume and hypertension, thereby contributing to LVH<sup>
<xref rid="X95" ref-type="bibr">94)</xref>
</sup>. The renin&#8211;angiotensin&#8211;aldosterone system (RAAS) is a neurohormonal signaling pathway that plays a crucial role in regulating blood pressure and influences the development and progression of LVH<sup>
<xref rid="X96" ref-type="bibr">95)</xref>
</sup>. RAAS-blocking medications, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers, have been shown to improve LVH and reduce cardiovascular mortality<sup>
<xref rid="X97" ref-type="bibr">96)</xref>
</sup>. FGF23 may stimulate renin production in the kidneys by suppressing the production of 1,25-(OH)<sub>2</sub>D<sup>
<xref rid="X98" ref-type="bibr">97)</xref>
</sup>. Additionally, FGF23 may reduce the expression of ACE2 <sup>
<xref rid="X99" ref-type="bibr">98)</xref>
</sup>, an enzyme that converts angiotensin-2 into vasodilatory angiotensin-(1-7), leading to cardiac hypertrophy and myocardial fibrosis. However, further research is required to fully understand the relationship between FGF23 and the RAAS.
</p><p>
Vascular calcification, characterized by the deposition of calcium phosphate minerals in arterial walls, is a complex pathological process influenced by various factors, including inflammation, oxidative stress, and interactions between cellular and molecular processes<sup>
<xref rid="X100" ref-type="bibr">99)</xref>
</sup>. Large prospective studies have demonstrated that vascular calcification is associated with an increased risk of cardiovascular morbidity and mortality<sup>
<xref rid="X101" ref-type="bibr">100</xref>
,
<xref rid="X102" ref-type="bibr">101)</xref>
</sup>. Observational studies on patients with coronary artery disease have revealed the existence of a relationship between the FGF23/&#945;Klotho axis and the occurrence of coronary artery disease and aortic valve calcifications<sup>
<xref rid="X103" ref-type="bibr">102</xref>
,
<xref rid="X104" ref-type="bibr">103)</xref>
</sup>.
</p><p>
When serum calcium phosphate levels increase because of disturbances in mineral homeostasis, serum fetuin-A binds to it, forming amorphous calciprotein particles (CPPs)<sup>
<xref rid="X105" ref-type="bibr">104</xref>
,
<xref rid="X106" ref-type="bibr">105)</xref>
</sup>. CPPs prevent calcium phosphate precipitation in the blood and helps to transport calcium phosphate from the intestines to the bones. However, under certain conditions, CPPs can transform from small, harmless, amorphous, spherical complexes (primary CPPs) into harmful, large crystalline complexes (secondary CPPs). Studies suggest that increase in either the calcium or phosphate concentration in cultured osteoblasts triggers FGF23 expression, and this response is influenced by CPP formation. For instance, mice receiving a continuous high-phosphate diet exhibited greater FGF23 and CPP levels than those receiving intermittent bolus phosphate<sup>
<xref rid="X107" ref-type="bibr">106)</xref>
</sup>. This suggests that persistent hyperphosphatemia, as seen in CKD, may lead to more CPP formation than temporary dietary phosphate spikes. Clinical studies in patients with CKD have shown that serum CPP levels are associated with coronary artery calcification, as measured by calcium scores<sup>
<xref rid="X108" ref-type="bibr">107)</xref>
</sup>, vascular stiffness<sup>
<xref rid="X109" ref-type="bibr">108)</xref>
</sup>, and inflammation<sup>
<xref rid="X110" ref-type="bibr">109</xref>
,
<xref rid="X111" ref-type="bibr">110)</xref>
</sup>. These findings suggest that even in patients without renal dysfunction, CPPs might be an early trigger for increased FGF23 production in osteoblasts.
</p><p>
Previous Mendelian randomization studies have identified LDL-C and lipoprotein(a) as causal risk factors for aortic valve calcification<sup>
<xref rid="X112" ref-type="bibr">111</xref>
,
<xref rid="X113" ref-type="bibr">112)</xref>
</sup>. However, subsequent large randomized clinical trials have shown that LDL-C-lowering therapy failed to inhibit disease progression<sup>
<xref rid="X114" ref-type="bibr">113)</xref>
</sup>. Nonetheless, statins retain the recognized advantages in treating patients at significant risk of atherosclerosis.
</p><p>
A study using the Multi-Ethnic Study of Atherosclerosis dataset showed that elevated serum phosphate levels were associated with increased prevalence of aortic valve calcification. However, other biomarkers such as FGF23, PTH, and urine phosphate were not significantly associated with aortic valve calcification. The study concluded that phosphate metabolism biomarkers were not strongly associated with aortic valve calcification, except in the highest quartile of FGF23 <sup>
<xref rid="X115" ref-type="bibr">114)</xref>
</sup>. Klotho-deficient mouse models exhibit premature aging and develop calcified nodules in the aortic valve hinge region without leaflet thickening, extracellular matrix disorganization, or inflammation. In the aortic valves of Klotho-deficient mice, increased <italic toggle="yes">Runx2</italic> expression was observed, indicating the presence of calcification, along with the increased expression of <italic toggle="yes">Sox9</italic> and elevated levels of collagen 10a1 and osteopontin<sup>
<xref rid="X116" ref-type="bibr">115)</xref>
</sup>. Studies on human calcified aortic valves have revealed increased activation of bone morphogenetic protein (BMP) signaling around the calcified aortic valves<sup>
<xref rid="X117" ref-type="bibr">116)</xref>
</sup>. Moreover, enhanced BMP signaling and osteochondrogenic activation are observed in Klotho-deficient mice and calcified porcine aortic valve interstitial cells<sup>
<xref rid="X118" ref-type="bibr">117)</xref>
</sup>. Thus, interactions between the FGF23 and BMP signaling pathways may contribute to the pathogenesis and progression of aortic stenosis.
</p><p>
A study involving 708 patients with calcific aortic stenosis analyzed the correlation between 49 biomarkers and the risk of death or heart failure-related hospital admission. Several biomarkers were found to be significant predictors of death and heart failure-related hospital admissions. Machine learning models have highlighted interleukin (IL)-6 and FGF23 as the most prominent biomarkers associated with adverse outcomes<sup>
<xref rid="X119" ref-type="bibr">118)</xref>
</sup>. The progression of aortic stenosis may require not only FGF23 activation but also an inflammatory response<sup>
<xref rid="X120" ref-type="bibr">119)</xref>
</sup>.
</p><p>
Atrial fibrillation (AF), the most prevalent cardiac arrhythmia in older adults, greatly increases the risk of stroke, heart failure, and CVD mortality<sup>
<xref rid="X121" ref-type="bibr">120)</xref>
</sup>. Previous studies investigating the relationship between FGF23 and AF have reported inconsistent results. Two large, community-based cohort studies, excluding individuals with baseline CVDs, reported the existence of an association between elevated FGF23 levels and AF development, potentially shedding light on the link between CKD and AF<sup>
<xref rid="X122" ref-type="bibr">121)</xref>
</sup>. Similarly, studies in patients with CKD demonstrated an independent association between elevated FGF23 levels and both prevalent and incident AF<sup>
<xref rid="X123" ref-type="bibr">122)</xref>
</sup>. However, this association was not observed in the Atherosclerosis Risk in Communities Study<sup>
<xref rid="X124" ref-type="bibr">123)</xref>
</sup>. Differences in study design and population characteristics, such as varying prevalence of CKD, exclusion of individuals with CVDs, and follow-up duration, might explain these inconsistencies.
</p><p>
FGF23 may be associated with AF via its direct effects on the myocardium. Animal and clinical studies suggest a correlation between increased FGF23 levels and high LVH and lower ejection fraction<sup>
<xref rid="X125" ref-type="bibr">124</xref>
,
<xref rid="X126" ref-type="bibr">125)</xref>
</sup>. However, the precise mechanism underlying FGF23&#8217;s potential negative cardiac effects remain unclear because of the presumed absence of &#945;Klotho, a co-factor of FGF23, in myocardial cells. FGF23 might exert its direct cardiac effects through a non-canonical FGF23-FGFR4 axis, independent of &#945;Klotho and FGF23-FGFR1 axis <bold>
(
<xref rid="X14" ref-type="fig">Fig.4</xref>
)
</bold>.
</p><fig position="float" id="X14" orientation="portrait"><label>Fig.4. Regulation and effects of FGF23</label><caption><p>The effects of FGF23 can be classified into canonical and non-canonical effects. The canonical effects of FGF23 mainly involve the regulation of phosphate and vitamin D metabolism through specific receptors and co-receptor &#945;Klotho. The non-canonical effects of FGF23 are mediated through signaling pathways independent of &#945;Klotho.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="31_RV22025_4.jpg"/></fig><p>
Independent associations have been established between high FGF23 levels and inflammatory markers, such as IL-6, C-reactive protein, tumor necrosis factor-&#945;, and fibrinogen<sup>
<xref rid="X127" ref-type="bibr">126)</xref>
</sup>, as well as vascular dysfunction<sup>
<xref rid="X128" ref-type="bibr">127</xref>
-
<xref rid="X129" ref-type="bibr">129)</xref>
</sup>. Additionally, the relationship between FGF23 and AF might be influenced by the suppression of 1,25-(OH)<sub>2</sub>D, the active form of vitamin D. The PRIMO trial investigated the effects of vitamin D therapy on the cardiac structure and function over 48 weeks<sup>
<xref rid="X130" ref-type="bibr">130)</xref>
</sup>. Although no significant differences emerged in left ventricular volume index between the treatment and placebo groups, there were significant differences in the left atrial volume index, brain natriuretic peptide levels, and congestive heart failure hospitalizations between the two groups<sup>
<xref rid="X131" ref-type="bibr">131)</xref>
</sup>. Additional research is needed to fully understand the mechanisms underlying these associations and determine whether FGF23 could be a useful biomarker or therapeutic target for AF.
</p><p>
Elevated serum phosphate levels in patients undergoing maintenance dialysis are associated with an increased risk of CVDs and mortality<sup>
<xref rid="X132" ref-type="bibr">132)</xref>
</sup>. Current phosphate management approaches include dietary phosphate restriction and phosphate binder therapy. Based on molecular structures, phosphate binders can be categorized as calcium-based (calcium carbonate and calcium acetate), non-calcium-containing (sevelamer carbonate, sevelamer hydrochloride, and lanthanum carbonate), aluminum-containing (aluminum hydroxide), or iron-based (sucroferric oxyhydroxide and ferric citrate) compounds. Phosphate binder therapy has many side effects, such as constipation, diarrhea, and nausea, and requires frequent dosing, resulting in high pill burden. A recent systematic review of randomized controlled trials evaluated the efficacy of non-calcium-based phosphate-lowering treatments in patients with non-dialysis CKD<sup>
<xref rid="X133" ref-type="bibr">133)</xref>
</sup>. The meta-analysis revealed that calcium-free phosphorus adsorbents reduced serum and urinary phosphate levels compared to the placebo. However, their use was associated with increased incidence of constipation and vascular calcification, and they demonstrated limited effectiveness in mitigating cardiovascular risk.
</p><p>
In patients undergoing maintenance hemodialysis, 12 months of strict phosphate control with sucroferric oxyhydroxide or lanthanum carbonate delayed the progression of coronary artery calcification compared to standard phosphate control<sup>
<xref rid="X134" ref-type="bibr">134)</xref>
</sup>. Notably, both medications achieved similar results, suggesting minimal differences in their efficacy. Furthermore, the extent of coronary artery calcification was found to be associated with serum phosphate concentration. Interestingly, the coronary artery calcification scores decreased after a year of strict phosphate control therapy, indicating potential reversibility of established calcified lesions. Further studies are warranted to determine whether targeting phosphate levels within the normal range can improve prognosis.
</p><p>Tenapanor acts as a non-absorbable inhibitor of the sodium-proton exchanger (NHE3) in the gastrointestinal tract, thereby reducing sodium absorption. This leads to increase in luminal sodium levels, which in turn reduces the phosphate absorption, ultimately lowering serum phosphate levels.</p></sec></sec></sec><sec id="X15"><title>Conclusion</title><p>The FGF family plays an important role in the physiology and pathophysiology of cardiovascular health. The diverse functions of FGFs, from embryonic development to metabolic regulation and tissue repair, highlight their potential as therapeutic targets for CVDs. Despite the current advancements in CVD treatment, a considerable burden remains due to the limitations of existing therapies. For instance, FGF1 and FGF2 have shown potential in promoting angiogenesis and improving cardiac function in clinical studies. FGF19 is essential for metabolic regulation, whereas FGF21 and FGF23 are important regulators of cardiometabolic health and phosphate metabolism, respectively. Understanding and targeting the diverse roles of FGFs may lead to novel therapeutic strategies for mitigating the substantial burden of CVDs.</p></sec><sec id="X16"><title>Acknowledgements and Notice of Grant Support</title><p>None.</p></sec><sec sec-type="COI-statement" id="X17"><title>Conflict of Interest</title><p>No potential conflicts of interest were disclosed.</p></sec></body><back><ref-list><ref id="X19"><label>1)</label><mixed-citation publication-type="journal">Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, Barengo NC, Beaton AZ, Benjamin EJ, Benziger CP, Bonny A, Brauer M, Brodmann M, Cahill TJ, Carapetis J, Catapano AL, Chugh SS, Cooper LT, Coresh J, Criqui M, DeCleene N, Eagle KA, Emmons-Bell S, Feigin VL, Fern&#225;ndez-Sol&#224; J, Fowkes G, Gakidou E, Grundy SM, He FJ, Howard G, Hu F, Inker L, Karthikeyan G, Kassebaum N, Koroshetz W, Lavie C, Lloyd-Jones D, Lu HS, Mirijello A, Temesgen AM, Mokdad A, Moran AE, Muntner P, Narula J, Neal B, Ntsekhe M, Moraes de Oliveira G, Otto C, Owolabi M, Pratt M, Rajagopalan S, Reitsma M, Ribeiro ALP, Rigotti N, Rodgers A, Sable C, Shakil S, Sliwa-Hahnle K, Stark B, Sundstr&#246;m J, Timpel P, Tleyjeh IM, Valgimigli M, Vos T, Whelton PK, Yacoub M, Zuhlke L, Murray C, and Fuster V: Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol, 2020; 76: 2982-3021<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2020.11.010</pub-id><pub-id pub-id-type="pmcid">PMC7755038</pub-id><pub-id pub-id-type="pmid">33309175</pub-id></mixed-citation></ref><ref id="X20"><label>2)</label><mixed-citation publication-type="journal">Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, and Ornitz DM: Receptor specificity of the fibroblast growth factor family: the complete mammalian FGF family. J Biol Chem, 2006; 281: 15694-15700<pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M601252200</pub-id><pub-id pub-id-type="pmcid">PMC2080618</pub-id><pub-id pub-id-type="pmid">16597617</pub-id></mixed-citation></ref><ref id="X21"><label>3)</label><mixed-citation publication-type="journal">Ornitz DM and Itoh N: The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip Rev Dev Biol, 2015; 4: 215-266<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/wdev.176</pub-id><pub-id pub-id-type="pmcid">PMC4393358</pub-id><pub-id pub-id-type="pmid">25772309</pub-id></mixed-citation></ref><ref id="X22"><label>4)</label><mixed-citation publication-type="journal">Beenken A and Mohammadi M: The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov, 2009; 8: 235-253<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd2792</pub-id><pub-id pub-id-type="pmcid">PMC3684054</pub-id><pub-id pub-id-type="pmid">19247306</pub-id></mixed-citation></ref><ref id="X23"><label>5)</label><mixed-citation publication-type="journal">Beenken A and Mohammadi M: The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov, 2009; 8: 235-253<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd2792</pub-id><pub-id pub-id-type="pmcid">PMC3684054</pub-id><pub-id pub-id-type="pmid">19247306</pub-id></mixed-citation></ref><ref id="X24"><label>6)</label><mixed-citation publication-type="journal">Farooq M, Khan AW, Kim MS, and Choi S: The role of fibroblast growth factor (FGF) signaling in tissue repair and regeneration. Cells, 2021; 10: 3242<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells10113242</pub-id><pub-id pub-id-type="pmcid">PMC8622657</pub-id><pub-id pub-id-type="pmid">34831463</pub-id></mixed-citation></ref><ref id="B7"><label>7)</label><mixed-citation publication-type="journal">Feldman B, Poueymirou W, Papaioannou VE, DeChiara TM, and Goldfarb M: Requirement of FGF-4 for postimplantation mouse development. Science, 1995; 267: 246-249<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.7809630</pub-id><pub-id pub-id-type="pmid">7809630</pub-id></mixed-citation></ref><ref id="B8"><label>8)</label><mixed-citation publication-type="journal">H&#233;bert JM, Rosenquist T, G&#246;tz J, and Martin GR: FGF5 as a regulator of the hair growth cycle: evidence from targeted and spontaneous mutations. Cell, 1994; 78: 1017-1025<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0092-8674(94)90276-3</pub-id><pub-id pub-id-type="pmid">7923352</pub-id></mixed-citation></ref><ref id="B9"><label>9)</label><mixed-citation publication-type="journal">Armand AS, Laziz I, and Chanoine C: FGF6 in myogenesis. Biochim Biophys Acta, 2006; 1763: 773-778<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbamcr.2006.06.005</pub-id><pub-id pub-id-type="pmid">16875743</pub-id></mixed-citation></ref><ref id="B10"><label>10)</label><mixed-citation publication-type="journal">Tekin M, Hi&#351;mi BO, Fitoz S, Ozda&#287; H, Cengiz FB, Sirmaci A, Aslan I, Inceo&#287;lu B, Y&#252;ksel-Konuk EB, Yilmaz ST, Yasun O, and Akar N: Homozygous mutations in fibroblast growth factor 3 are associated with a new form of syndromic deafness characterized by inner ear agenesis, microtia, and microdontia. Am J Hum Genet, 2007; 80: 338-344<pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/510920</pub-id><pub-id pub-id-type="pmcid">PMC1785350</pub-id><pub-id pub-id-type="pmid">17236138</pub-id></mixed-citation></ref><ref id="B11"><label>11)</label><mixed-citation publication-type="journal">Qiao J, Uzzo R, Obara-Ishihara T, Degenstein L, Fuchs E, and Herzlinger D: FGF-7 modulates ureteric bud growth and nephron number in the developing kidney. Development, 1999; 126: 547-554<pub-id pub-id-type="doi" assigning-authority="pmc">10.1242/dev.126.3.547</pub-id><pub-id pub-id-type="pmid">9876183</pub-id></mixed-citation></ref><ref id="B12"><label>12)</label><mixed-citation publication-type="journal">Kato S and Sekine K: FGF-FGFR signaling in vertebrate organogenesis. Cell Mol Biol (Noisy-Le-Grand), 1999; 45: 631-638<pub-id pub-id-type="pmid">10512194</pub-id></mixed-citation></ref><ref id="B13"><label>13)</label><mixed-citation publication-type="journal">Umemori H, Linhoff MW, Ornitz DM, and Sanes JR: FGF22 and its close relatives are presynaptic organizing molecules in the mammalian brain. Cell, 2004; 118: 257-270<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2004.06.025</pub-id><pub-id pub-id-type="pmid">15260994</pub-id></mixed-citation></ref><ref id="B14"><label>14)</label><mixed-citation publication-type="journal">Liu A and Joyner AL: Early anterior/posterior patterning of the midbrain and cerebellum. Annu Rev Neurosci, 2001; 24: 869-896<pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.neuro.24.1.869</pub-id><pub-id pub-id-type="pmid">11520921</pub-id></mixed-citation></ref><ref id="B15"><label>15)</label><mixed-citation publication-type="journal">Xu J, Liu Z, and Ornitz DM: Temporal and spatial gradients of Fgf8 and Fgf17 regulate proliferation and differentiation of midline cerebellar structures. Development, 2000; 127: 1833-1843<pub-id pub-id-type="doi" assigning-authority="pmc">10.1242/dev.127.9.1833</pub-id><pub-id pub-id-type="pmid">10751172</pub-id></mixed-citation></ref><ref id="B16"><label>16)</label><mixed-citation publication-type="journal">Liu Z, Xu J, Colvin JS, and Ornitz DM: Coordination of chondrogenesis and osteogenesis by fibroblast growth factor 18. Genes Dev, 2002; 16: 859-869<pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/gad.965602</pub-id><pub-id pub-id-type="pmcid">PMC186326</pub-id><pub-id pub-id-type="pmid">11937493</pub-id></mixed-citation></ref><ref id="B17"><label>17)</label><mixed-citation publication-type="journal">Colvin JS, Green RP, Schmahl J, Capel B, and Ornitz DM: Male-to-female sex reversal in mice lacking fibroblast growth factor 9. Cell, 2001; 104: 875-889<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0092-8674(01)00284-7</pub-id><pub-id pub-id-type="pmid">11290325</pub-id></mixed-citation></ref><ref id="B18"><label>18)</label><mixed-citation publication-type="journal">Lu SY, Sheikh F, Sheppard PC, Fresnoza A, Duckworth ML, Detillieux KA, and Cattini PA: FGF-16 is required for embryonic heart development. Biochem Biophys Res Commun, 2008; 373: 270-274<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2008.06.029</pub-id><pub-id pub-id-type="pmcid">PMC5233434</pub-id><pub-id pub-id-type="pmid">18565327</pub-id></mixed-citation></ref><ref id="X25"><label>19)</label><mixed-citation publication-type="journal">Ohmachi S, Mikami T, Konishi M, Miyake A, and Itoh N: Preferential neurotrophic activity of fibroblast growth factor-20 for dopaminergic neurons through fibroblast growth factor receptor-1c. J Neurosci Res, 2003; 72: 436-443<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jnr.10592</pub-id><pub-id pub-id-type="pmid">12704805</pub-id></mixed-citation></ref><ref id="X26"><label>20)</label><mixed-citation publication-type="journal">Armelin HA: Pituitary extracts and steroid hormones in the control of 3T3 cell growth. Proc Natl Acad Sci U S A, 1973; 70: 2702-2706<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.70.9.2702</pub-id><pub-id pub-id-type="pmcid">PMC427087</pub-id><pub-id pub-id-type="pmid">4354860</pub-id></mixed-citation></ref><ref id="X27"><label>21)</label><mixed-citation publication-type="journal">Gospodarowicz D: Localisation of a fibroblast growth factor and its effect alone and with hydrocortisone on 3T3 cell growth. Nature, 1974; 249: 123-127<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/249123a0</pub-id><pub-id pub-id-type="pmid">4364816</pub-id></mixed-citation></ref><ref id="X28"><label>22)</label><mixed-citation publication-type="journal">Caron A, Michelet S, Caron A, Sordello S, Ivanov MA, Dela&#232;re P, Branellec D, Schwartz B, and Emmanuel F: Human FGF-1 gene transfer promotes the formation of collateral vessels and arterioles in ischemic muscles of hypercholesterolemic hamsters. J Gene Med, 2004; 6: 1033-1045<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jgm.594</pub-id><pub-id pub-id-type="pmid">15352076</pub-id></mixed-citation></ref><ref id="X29"><label>23)</label><mixed-citation publication-type="journal">Schumacher B, Pecher P, von Specht BU, and Stegmann T: Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation, 1998; 97: 645-650<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.cir.97.7.645</pub-id><pub-id pub-id-type="pmid">9495299</pub-id></mixed-citation></ref><ref id="X30"><label>24)</label><mixed-citation publication-type="journal">Pecher P and Schumacher BA: Angiogenesis in ischemic human myocardium: clinical results after 3 years. Ann Thorac Surg, 2000; 69: 1414-1419<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0003-4975(00)01162-0</pub-id><pub-id pub-id-type="pmid">10881815</pub-id></mixed-citation></ref><ref id="X31"><label>25)</label><mixed-citation publication-type="journal">Comerota AJ, Throm RC, Miller KA, Henry T, Chronos N, Laird J, Sequeira R, Kent CK, Bacchetta M, Goldman C, Salenius JP, Schmieder FA, and Pilsudski R: Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg, 2002; 35: 930-936<pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mva.2002.123677</pub-id><pub-id pub-id-type="pmid">12021709</pub-id></mixed-citation></ref><ref id="X32"><label>26)</label><mixed-citation publication-type="journal">Nikol S, Baumgartner I, Van Belle E, Diehm C, Vison&#225; A, Capogrossi MC, Ferreira-Maldent N, Gallino A, Wyatt MG, Wijesinghe LD, Fusari M, Stephan D, Emmerich J, Pompilio G, Vermassen F, Pham E, Grek V, Coleman M, and Meyer F: Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther, 2008; 16: 972-978<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mt.2008.33</pub-id><pub-id pub-id-type="pmid">28178491</pub-id></mixed-citation></ref><ref id="X33"><label>27)</label><mixed-citation publication-type="journal">Belch J, Hiatt WR, Baumgartner I, Driver IV, Nikol S, Norgren L, and Van Belle E: Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet, 2011; 377: 1929-1937<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(11)60394-2</pub-id><pub-id pub-id-type="pmid">21621834</pub-id></mixed-citation></ref><ref id="X34"><label>28)</label><mixed-citation publication-type="journal">Ware JA and Simons M: Angiogenesis in ischemic heart disease. Nat Med, 1997; 3: 158-164<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm0297-158</pub-id><pub-id pub-id-type="pmid">9018233</pub-id></mixed-citation></ref><ref id="X35"><label>29)</label><mixed-citation publication-type="journal">Scholz D, Cai WJ, and Schaper W: Arteriogenesis, a new concept of vascular adaptation in occlusive disease. Angiogenesis, 2001; 4: 247-257<pub-id pub-id-type="doi" assigning-authority="pmc">10.1023/a:1016094004084</pub-id><pub-id pub-id-type="pmid">12197469</pub-id></mixed-citation></ref><ref id="X36"><label>30)</label><mixed-citation publication-type="journal">Unger EF, Goncalves L, Epstein SE, Chew EY, Trapnell CB, Cannon III RO, and Quyyumi AA: Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris. Am J Cardiol, 2000; 85: 1414-1419<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0002-9149(00)00787-6</pub-id><pub-id pub-id-type="pmid">10856385</pub-id></mixed-citation></ref><ref id="X37"><label>31)</label><mixed-citation publication-type="journal">Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H, Udelson JE, Gervino EV, Pike M, Whitehouse MJ, Moon T, and Chronos NA: Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation, 2002; 105: 788-793<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/hc0802.104407</pub-id><pub-id pub-id-type="pmid">11854116</pub-id></mixed-citation></ref><ref id="X38"><label>32)</label><mixed-citation publication-type="journal">Ruel M, Laham RJ, Parker JA, Post MJ, Ware JA, Simons M, and Sellke FW: Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg, 2002; 124: 28-34<pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mtc.2002.121974</pub-id><pub-id pub-id-type="pmid">12091805</pub-id></mixed-citation></ref><ref id="X39"><label>33)</label><mixed-citation publication-type="journal">Lazarous DF, Unger EF, Epstein SE, Stine A, Arevalo JL, Chew EY, and Quyyumi AA: Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial. J Am Coll Cardiol, 2000; 36: 1239-1244<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0735-1097(00)00882-2</pub-id><pub-id pub-id-type="pmid">11028477</pub-id></mixed-citation></ref><ref id="X40"><label>34)</label><mixed-citation publication-type="journal">Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ, and Annex BH: Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet, 2002; 359: 2053-2058<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0140-6736(02)08937-7</pub-id><pub-id pub-id-type="pmid">12086757</pub-id></mixed-citation></ref><ref id="X41"><label>35)</label><mixed-citation publication-type="journal">Taira M, Yoshida T, Miyagawa K, Sakamoto H, Terada M, and Sugimura T: cDNA sequence of human transforming gene hst and identification of the coding sequence required for transforming activity. Proc Natl Acad Sci U S A, 1987; 84: 2980-2984<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.84.9.2980</pub-id><pub-id pub-id-type="pmcid">PMC304784</pub-id><pub-id pub-id-type="pmid">2953031</pub-id></mixed-citation></ref><ref id="X42"><label>36)</label><mixed-citation publication-type="journal">Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD, West A, Rade JJ, Marrott P, Hammond HK, and Engler RL: Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation, 2002; 105: 1291-1297<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/hc1102.105595</pub-id><pub-id pub-id-type="pmid">11901038</pub-id></mixed-citation></ref><ref id="X43"><label>37)</label><mixed-citation publication-type="journal">Grines CL, Watkins MW, Mahmarian JJ, Iskandrian AE, Rade JJ, Marrott P, Pratt C, Kleiman N, and Angiogenic GENe Therapy (AGENT-2) Study Group: A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol, 2003; 42: 1339-1347<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0735-1097(03)00988-4</pub-id><pub-id pub-id-type="pmid">14563572</pub-id></mixed-citation></ref><ref id="X44"><label>38)</label><mixed-citation publication-type="journal">Henry TD, Grines CL, Watkins MW, Dib N, Barbeau G, Moreadith R, Andrasfay T, and Engler RL: Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol, 2007; 50: 1038-1046<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2007.06.010</pub-id><pub-id pub-id-type="pmid">17825712</pub-id></mixed-citation></ref><ref id="X45"><label>39)</label><mixed-citation publication-type="journal">Kaski JC and Consuegra-Sanchez L: Evaluation of ASPIRE trial: a Phase III pivotal registration trial, using intracoronary administration of Generx (Ad5FGF4) to treat patients with recurrent angina pectoris. Expert Opin Biol Ther, 2013; 13: 1749-1753<pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/14712598.2013.827656</pub-id><pub-id pub-id-type="pmid">23957658</pub-id></mixed-citation></ref><ref id="X46"><label>40)</label><mixed-citation publication-type="journal">Dor Y, Djonov V, Abramovitch R, Itin A, Fishman GI, Carmeliet P, Goelman G, and Keshet E: Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J, 2002; 21: 1939-1947<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/emboj/21.8.1939</pub-id><pub-id pub-id-type="pmcid">PMC125962</pub-id><pub-id pub-id-type="pmid">11953313</pub-id></mixed-citation></ref><ref id="X47"><label>41)</label><mixed-citation publication-type="journal">Dolegowska K, Marchelek-Mysliwiec M, Nowosiad-Magda M, Slawinski M, and Dolegowska B: FGF19 subfamily members: FGF19 and FGF21. J Physiol Biochem, 2019; 75: 229-240<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13105-019-00675-7</pub-id><pub-id pub-id-type="pmcid">PMC6611749</pub-id><pub-id pub-id-type="pmid">30927227</pub-id></mixed-citation></ref><ref id="X48"><label>42)</label><mixed-citation publication-type="journal">Walters JRF: Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol, 2014; 11: 426-434<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrgastro.2014.32</pub-id><pub-id pub-id-type="pmid">24662279</pub-id></mixed-citation></ref><ref id="X49"><label>43)</label><mixed-citation publication-type="journal">Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, and Kliewer SA: Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab, 2005; 2: 217-225<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2005.09.001</pub-id><pub-id pub-id-type="pmid">16213224</pub-id></mixed-citation></ref><ref id="X50"><label>44)</label><mixed-citation publication-type="journal">Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K, Xu HE, Shulman GI, Kliewer SA, and Mangelsdorf DJ: FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science, 2011; 331: 1621-1624<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1198363</pub-id><pub-id pub-id-type="pmcid">PMC3076083</pub-id><pub-id pub-id-type="pmid">21436455</pub-id></mixed-citation></ref><ref id="X51"><label>45)</label><mixed-citation publication-type="journal">Zhou M, Learned RM, Rossi SJ, Tian H, DePaoli AM, and Ling L: Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis. J Lipid Res, 2019; 60: 550-565<pub-id pub-id-type="doi" assigning-authority="pmc">10.1194/jlr.M089961</pub-id><pub-id pub-id-type="pmcid">PMC6399511</pub-id><pub-id pub-id-type="pmid">30679232</pub-id></mixed-citation></ref><ref id="X52"><label>46)</label><mixed-citation publication-type="journal">Wong YK, Cheung CYY, Tang CS, Au KW, Hai JSH, Lee CH, Lau KK, Cheung BMY, Sham PC, Xu A, Lam KSL, and Tse HF: Age-biomarkers-clinical risk factors for prediction of cardiovascular events in patients with coronary artery disease. Arterioscler Thromb Vasc Biol, 2018; 38: 2519-2527<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/ATVBAHA.118.311726</pub-id><pub-id pub-id-type="pmid">30354221</pub-id></mixed-citation></ref><ref id="X53"><label>47)</label><mixed-citation publication-type="journal">Xu W, Wang Y, Guo Y, Liu J, Ma L, Cao W, Yu B, and Zhou Y: Fibroblast growth factor 19 improves cardiac function and mitochondrial energy homoeostasis in the diabetic heart. Biochem Biophys Res Commun, 2018; 505: 242-248<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2018.09.046</pub-id><pub-id pub-id-type="pmid">30243718</pub-id></mixed-citation></ref><ref id="X54"><label>48)</label><mixed-citation publication-type="journal">Rinella ME: Nonalcoholic fatty liver disease: a systematic review. JAMA, 2015; 313: 2263-2273<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2015.5370</pub-id><pub-id pub-id-type="pmid">26057287</pub-id></mixed-citation></ref><ref id="X55"><label>49)</label><mixed-citation publication-type="journal">Harrison SA, Rinella ME, Abdelmalek MF, Trotter JF, Paredes AH, Arnold HL, Kugelmas M, Bashir MR, Jaros MJ, Ling L, Rossi SJ, DePaoli AM, and Loomba R: NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, 2018; 391: 1174-1185<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(18)30474-4</pub-id><pub-id pub-id-type="pmid">29519502</pub-id></mixed-citation></ref><ref id="X56"><label>50)</label><mixed-citation publication-type="journal">Harrison SA, Abdelmalek MF, Neff G, Gunn N, Guy CD, Alkhouri N, Bashir MR, Freilich B, Kohli A, Khazanchi A, Sheikh MY, Leibowitz M, Rinella ME, Siddiqui MS, Kipnes M, Moussa SE, Younes ZH, Bansal M, Baum SJ, Borg B, Ruane PJ, Thuluvath PJ, Gottwald M, Khan M, Chen C, Melchor-Khan L, Chang W, DePaoli AM, Ling L, and Lieu HD: Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol, 2022; 7: 603-616<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2468-1253(22)00017-6</pub-id><pub-id pub-id-type="pmid">35325622</pub-id></mixed-citation></ref><ref id="X57"><label>51)</label><mixed-citation publication-type="journal">Madan S, Mehra MR: The heart-gut microbiome axis in advanced heart failure. J Heart Lung Transplant, 2020; 39: 891-893<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.healun.2020.04.003</pub-id><pub-id pub-id-type="pmid">32327221</pub-id></mixed-citation></ref><ref id="X58"><label>52)</label><mixed-citation publication-type="journal">Vasavan T, Ferraro E, Ibrahim E, Dixon P, Gorelik J, and Williamson C: Heart and bile acids - clinical consequences of altered bile acid metabolism. Biochim Biophys Acta Mol Basis Dis, 2018; 1864: 1345-1355<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbadis.2017.12.039</pub-id><pub-id pub-id-type="pmid">29317337</pub-id></mixed-citation></ref><ref id="X59"><label>53)</label><mixed-citation publication-type="journal">Mor&#243;n-Ros S, Blasco-Roset A, Navarro-Gascon A, Rup&#233;rez C, Zamora M, Crispi F, Uriarte I, Fern&#225;ndez-Barrena MG, Avila M, Ferrer-Curriu G, Lup&#243;n J, Bay&#233;s-Genis A, Villarroya F, Gavald&#224;-Navarro A, and Planavila A: A new FGF15/19-mediated gut-to-heart axis controls cardiac hypertrophy. J Pathol, 2023; 261: 335-348<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/path.6193</pub-id><pub-id pub-id-type="pmid">37650293</pub-id></mixed-citation></ref><ref id="X60"><label>54)</label><mixed-citation publication-type="journal">Nishimura T, Nakatake Y, Konishi M, and Itoh N: Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta, 2000; 1492: 203-206<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0167-4781(00)00067-1</pub-id><pub-id pub-id-type="pmid">10858549</pub-id></mixed-citation></ref><ref id="X61"><label>55)</label><mixed-citation publication-type="journal">Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, and Shanafelt AB: FGF-21 as a novel metabolic regulator. J Clin Invest, 2005; 115: 1627-1635<pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI23606</pub-id><pub-id pub-id-type="pmcid">PMC1088017</pub-id><pub-id pub-id-type="pmid">15902306</pub-id></mixed-citation></ref><ref id="X62"><label>56)</label><mixed-citation publication-type="journal">Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, Moller DE, and Kharitonenkov A: Fibroblast growth factor 21 corrects obesity in mice. Endocrinology, 2008; 149: 6018-6027<pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2008-0816</pub-id><pub-id pub-id-type="pmid">18687777</pub-id></mixed-citation></ref><ref id="X63"><label>57)</label><mixed-citation publication-type="journal">Wente W, Efanov AM, Brenner M, Kharitonenkov A, K&#246;ster A, Sandusky GE, Sewing S, Treinies I, Zitzer H, and Gromada J: Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes, 2006; 55: 2470-2478<pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db05-1435</pub-id><pub-id pub-id-type="pmid">16936195</pub-id></mixed-citation></ref><ref id="X64"><label>58)</label><mixed-citation publication-type="journal">Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt AB, and Etgen GJ: The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology, 2007; 148: 774-781<pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2006-1168</pub-id><pub-id pub-id-type="pmid">17068132</pub-id></mixed-citation></ref><ref id="X65"><label>59)</label><mixed-citation publication-type="journal">Adams AC, Yang C, Coskun T, Cheng CC, Gimeno RE, Luo Y, and Kharitonenkov A: The breadth of FGF21&#8217;s metabolic actions are governed by FGFR1 in adipose tissue. Mol Metab, 2012; 2: 31-37<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmet.2012.08.007</pub-id><pub-id pub-id-type="pmcid">PMC3757657</pub-id><pub-id pub-id-type="pmid">24024127</pub-id></mixed-citation></ref><ref id="X66"><label>60)</label><mixed-citation publication-type="journal">Ding X, Boney-Montoya J, Owen BM, Bookout AL, Coate KC, Mangelsdorf DJ, Kliewer SA: &#946;Klotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab, 2012; 16: 387-393<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2012.08.002</pub-id><pub-id pub-id-type="pmcid">PMC3447537</pub-id><pub-id pub-id-type="pmid">22958921</pub-id></mixed-citation></ref><ref id="X67"><label>61)</label><mixed-citation publication-type="journal">Berglund ED, Li CY, Bina HA, Lynes SE, Michael MD, Shanafelt AB, Kharitonenkov A, and Wasserman DH: Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology, 2009; 150: 4084-4093<pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2009-0221</pub-id><pub-id pub-id-type="pmcid">PMC2736088</pub-id><pub-id pub-id-type="pmid">19470704</pub-id></mixed-citation></ref><ref id="X68"><label>62)</label><mixed-citation publication-type="journal">Fisher FM and Maratos-Flier E: Understanding the physiology of FGF21. Annu Rev Physiol, 2016; 78: 223-241<pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-physiol-021115-105339</pub-id><pub-id pub-id-type="pmid">26654352</pub-id></mixed-citation></ref><ref id="X69"><label>63)</label><mixed-citation publication-type="journal">Hughes SE: Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues. J Histochem Cytochem, 1997; 45: 1005-1019<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/002215549704500710</pub-id><pub-id pub-id-type="pmid">9212826</pub-id></mixed-citation></ref><ref id="X70"><label>64)</label><mixed-citation publication-type="journal">Lin Z, Tian H, Lam KS, Lin S, Hoo RC, Konishi M, Itoh N, Wang Y, Bornstein SR, Xu A, and Li X: Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab, 2013; 17: 779-789<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2013.04.005</pub-id><pub-id pub-id-type="pmid">23663741</pub-id></mixed-citation></ref><ref id="X71"><label>65)</label><mixed-citation publication-type="journal">Planavila A, Redondo I, Hondares E, Vinciguerra M, Munts C, Iglesias R, Gabrielli LA, Sitges M, Giralt M, van Bilsen M, and Villarroya F: Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun, 2013; 4: 2019<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ncomms3019</pub-id><pub-id pub-id-type="pmid">23771152</pub-id></mixed-citation></ref><ref id="X72"><label>66)</label><mixed-citation publication-type="journal">Li S, Zhu Z, Xue M, Yi X, Liang J, Niu C, Chen G, Shen Y, Zhang H, Zheng J, Zhao C, Liang Y, Cong W, Wang Y, and Jin L: Fibroblast growth factor 21 protects the heart from angiotensin II-induced cardiac hypertrophy and dysfunction via SIRT1. Biochim Biophys Acta Mol Basis Dis, 2019; 1865: 1241-1252<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbadis.2019.01.019</pub-id><pub-id pub-id-type="pmid">30677512</pub-id></mixed-citation></ref><ref id="X73"><label>67)</label><mixed-citation publication-type="journal">Liu SQ, Roberts D, Kharitonenkov A, Zhang B, Hanson SM, Li YC, Zhang LQ, and Wu YH: Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue. Sci Rep, 2013; 3: 2767<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep02767</pub-id><pub-id pub-id-type="pmcid">PMC3783882</pub-id><pub-id pub-id-type="pmid">24067542</pub-id></mixed-citation></ref><ref id="X74"><label>68)</label><mixed-citation publication-type="journal">Joki Y, Ohashi K, Yuasa D, Shibata R, Ito M, Matsuo K, Kambara T, Uemura Y, Hayakawa S, Hiramatsu-Ito M, Kanemura N, Ogawa H, Daida H, Murohara T, and Ouchi N: FGF21 attenuates pathological myocardial remodeling following myocardial infarction through the adiponectin-dependent mechanism. Biochem Biophys Res Commun, 2015; 459: 124-130<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2015.02.081</pub-id><pub-id pub-id-type="pmid">25712519</pub-id></mixed-citation></ref><ref id="X75"><label>69)</label><mixed-citation publication-type="journal">Kokkinos J, Tang S, Rye KA, and Ong KL: The role of fibroblast growth factor 21 in atherosclerosis. Atherosclerosis, 2017; 257: 259-265<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.atherosclerosis.2016.11.033</pub-id><pub-id pub-id-type="pmid">28012645</pub-id></mixed-citation></ref><ref id="X76"><label>70)</label><mixed-citation publication-type="journal">Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL, Kharitonenkov A, Bumol T, Schilske HK, and Moller DE: The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab, 2013; 18: 333-340<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2013.08.005</pub-id><pub-id pub-id-type="pmid">24011069</pub-id></mixed-citation></ref><ref id="X77"><label>71)</label><mixed-citation publication-type="journal">Talukdar S, Zhou Y, Li D, Rossulek M, Dong J, Somayaji V, Weng Y, Clark R, Lanba A, Owen BM, Brenner MB, Trimmer JK, Gropp KE, Chabot JR, Erion DM, Rolph TP, Goodwin B, and Calle RA: A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects. Cell Metab, 2016; 23: 427-440<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2016.02.001</pub-id><pub-id pub-id-type="pmid">26959184</pub-id></mixed-citation></ref><ref id="X78"><label>72)</label><mixed-citation publication-type="journal">Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, and Nabeshima YI: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature, 1997; 390: 45-51<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/36285</pub-id><pub-id pub-id-type="pmid">9363890</pub-id></mixed-citation></ref><ref id="B73"><label>73)</label><mixed-citation publication-type="journal">Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, and Yamashita T: Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature, 2006; 444: 770-774<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature05315</pub-id><pub-id pub-id-type="pmid">17086194</pub-id></mixed-citation></ref><ref id="X79"><label>74)</label><mixed-citation publication-type="journal">Yu X, Ibrahimi OA, Goetz R, Zhang F, Davis SI, Garringer HJ, Linhardt RJ, Ornitz DM, Mohammadi M, and White KE: Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology, 2005; 146: 4647-4656<pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2005-0670</pub-id><pub-id pub-id-type="pmcid">PMC4140631</pub-id><pub-id pub-id-type="pmid">16081635</pub-id></mixed-citation></ref><ref id="X80"><label>75)</label><mixed-citation publication-type="journal">Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, and Yamashita T: Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest, 2004; 113: 561-568<pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI19081</pub-id><pub-id pub-id-type="pmcid">PMC338262</pub-id><pub-id pub-id-type="pmid">14966565</pub-id></mixed-citation></ref><ref id="B76"><label>76)</label><mixed-citation publication-type="journal">Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, and Yamashita T: FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res, 2004; 19: 429-435<pub-id pub-id-type="doi" assigning-authority="pmc">10.1359/JBMR.0301264</pub-id><pub-id pub-id-type="pmid">15040831</pub-id></mixed-citation></ref><ref id="X81"><label>77)</label><mixed-citation publication-type="journal">Gattineni J, Bates C, Twombley K, Dwarakanath V, Robinson ML, Goetz R, Mohammadi M, and Baum M: FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol, 2009; 297: F282-91<pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/ajprenal.90742.2008</pub-id><pub-id pub-id-type="pmcid">PMC2724258</pub-id><pub-id pub-id-type="pmid">19515808</pub-id></mixed-citation></ref><ref id="X82"><label>78)</label><mixed-citation publication-type="journal">Isakova T, Wahl P, Vargas GS, Guti&#233;rrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, and Wolf M: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int, 2011; 79: 1370-1378<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ki.2011.47</pub-id><pub-id pub-id-type="pmcid">PMC3134393</pub-id><pub-id pub-id-type="pmid">21389978</pub-id></mixed-citation></ref><ref id="X83"><label>79)</label><mixed-citation publication-type="journal">Yamada S and Nakano T: Role of chronic kidney disease (CKD)-mineral and bone disorder (MBD) in the pathogenesis of cardiovascular disease in CKD. J Atheroscler Thromb, 2023; 30: 835-850<pub-id pub-id-type="doi" assigning-authority="pmc">10.5551/jat.RV22006</pub-id><pub-id pub-id-type="pmcid">PMC10406631</pub-id><pub-id pub-id-type="pmid">37258233</pub-id></mixed-citation></ref><ref id="X84"><label>80)</label><mixed-citation publication-type="journal">Guti&#233;rrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, J&#252;ppner H, and Wolf M: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med, 2008; 359: 584-592<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa0706130</pub-id><pub-id pub-id-type="pmcid">PMC2890264</pub-id><pub-id pub-id-type="pmid">18687639</pub-id></mixed-citation></ref><ref id="X85"><label>81)</label><mixed-citation publication-type="journal">Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Guti&#233;rrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, and Wolf M: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA, 2011; 305: 2432-2439<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2011.826</pub-id><pub-id pub-id-type="pmcid">PMC3124770</pub-id><pub-id pub-id-type="pmid">21673295</pub-id></mixed-citation></ref><ref id="X86"><label>82)</label><mixed-citation publication-type="journal">Ix JH, Katz R, Kestenbaum BR, de Boer IH, Chonchol M, Mukamal KJ, Rifkin D, Siscovick DS, Sarnak MJ, and Shlipak MG: Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol, 2012; 60: 200-207<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2012.03.040</pub-id><pub-id pub-id-type="pmcid">PMC3396791</pub-id><pub-id pub-id-type="pmid">22703926</pub-id></mixed-citation></ref><ref id="X87"><label>83)</label><mixed-citation publication-type="journal">Xue C, Yang B, Zhou C, Dai B, Liu Y, Mao Z, Yu S, and Mei C: Fibroblast growth factor 23 predicts all-cause mortality in a dose-response fashion in pre-dialysis patients with chronic kidney disease. Am J Nephrol, 2017; 45: 149-159<pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000454959</pub-id><pub-id pub-id-type="pmid">28006765</pub-id></mixed-citation></ref><ref id="X88"><label>84)</label><mixed-citation publication-type="journal">Liu M, Xia P, Tan Z, Song T, Mei K, Wang J, Ma J, Jiang Y, Zhang J, Zhao Y, Yu P, and Liu X: Fibroblast growth factor-23 and the risk of cardiovascular diseases and mortality in the general population: A systematic review and dose-response meta-analysis. Front Cardiovasc Med, 2022; 9: 989574<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcvm.2022.989574</pub-id><pub-id pub-id-type="pmcid">PMC9669381</pub-id><pub-id pub-id-type="pmid">36407457</pub-id></mixed-citation></ref><ref id="X89"><label>85)</label><mixed-citation publication-type="journal">Plischke M, Neuhold S, Adlbrecht C, Bielesz B, Shayganfar S, Bieglmayer C, Szekeres T, H&#246;rl WH, Strunk G, Vavken P, Pacher R, and H&#252;lsmann M: Inorganic phosphate and FGF-23 predict outcome in stable systolic heart failure. Eur J Clin Investig, 2012; 42: 649-656<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2362.2011.02631.x</pub-id><pub-id pub-id-type="pmid">22150123</pub-id></mixed-citation></ref><ref id="X90"><label>86)</label><mixed-citation publication-type="journal">Ter Maaten JM, Voors AA, Damman K, van der Meer P, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Metra M, Navis G, Ng L, Ouwerkerk W, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, and de Borst MH: Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. Int J Cardiol, 2018; 253: 84-90<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijcard.2017.10.010</pub-id><pub-id pub-id-type="pmid">29306478</pub-id></mixed-citation></ref><ref id="X91"><label>87)</label><mixed-citation publication-type="journal">Andersen IA, Huntley BK, Sandberg SS, Heublein DM, and Burnett Jr JC: Elevation of circulating but not myocardial FGF23 in human acute decompensated heart failure. Nephrol Dial Transplant, 2016; 31: 767-772<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ndt/gfv398</pub-id><pub-id pub-id-type="pmid">26666498</pub-id></mixed-citation></ref><ref id="X92"><label>88)</label><mixed-citation publication-type="journal">Mirza MA, Larsson A, Melhus H, Lind L, and Larsson TE: Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis, 2009; 207: 546-551<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.atherosclerosis.2009.05.013</pub-id><pub-id pub-id-type="pmid">19524924</pub-id></mixed-citation></ref><ref id="B89"><label>89)</label><mixed-citation publication-type="journal">Shibata K, Fujita S, Morita H, Okamoto Y, Sohmiya K, Hoshiga M, and Ishizaka N: Association between circulating fibroblast growth factor 23, &#945;-klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients. PLoS One, 2013; 8: e73184<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0073184</pub-id><pub-id pub-id-type="pmcid">PMC3767778</pub-id><pub-id pub-id-type="pmid">24039882</pub-id></mixed-citation></ref><ref id="B90"><label>90)</label><mixed-citation publication-type="journal">Kestenbaum B, Sachs MC, Hoofnagle AN, Siscovick DS, Ix JH, Robinson-Cohen C, Lima JA, Polak JF, Blondon M, Ruzinski J, Rock D, and de Boer IH: Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis. Circ Heart Fail, 2014; 7: 409-417<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCHEARTFAILURE.113.000952</pub-id><pub-id pub-id-type="pmcid">PMC4031265</pub-id><pub-id pub-id-type="pmid">24668259</pub-id></mixed-citation></ref><ref id="B91"><label>91)</label><mixed-citation publication-type="journal">Guti&#233;rrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, and Wolf M: Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation, 2009; 119: 2545-2552<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.108.844506</pub-id><pub-id pub-id-type="pmcid">PMC2740903</pub-id><pub-id pub-id-type="pmid">19414634</pub-id></mixed-citation></ref><ref id="X93"><label>92)</label><mixed-citation publication-type="journal">Patel RB, Ning H, de Boer IH, Kestenbaum B, Lima JAC, Mehta R, Allen NB, Shah SJ, and Lloyd-Jones DM: Fibroblast growth factor 23 and long-term cardiac function: the multi-ethnic study of atherosclerosis. Circ Cardiovasc Imaging, 2020; 13: e011925<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCIMAGING.120.011925</pub-id><pub-id pub-id-type="pmcid">PMC7665116</pub-id><pub-id pub-id-type="pmid">33161733</pub-id></mixed-citation></ref><ref id="X94"><label>93)</label><mixed-citation publication-type="journal">Grabner A, Amaral AP, Schramm K, Singh S, Sloan A, Yanucil C, Li J, Shehadeh LA, Hare JM, David V, Martin A, Fornoni A, Di Marco GS, Kentrup D, Reuter S, Mayer AB, Pavenst&#228;dt H, Stypmann J, Kuhn C, Hille S, Frey N, Leifheit-Nestler M, Richter B, Haffner D, Abraham R, Bange J, Sperl B, Ullrich A, Brand M, Wolf M, and Faul C: Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab, 2015; 22: 1020-1032<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2015.09.002</pub-id><pub-id pub-id-type="pmcid">PMC4670583</pub-id><pub-id pub-id-type="pmid">26437603</pub-id></mixed-citation></ref><ref id="X95"><label>94)</label><mixed-citation publication-type="journal">Andrukhova O, Slavic S, Smorodchenko A, Zeitz U, Shalhoub V, Lanske B, Pohl EE, and Erben RG: FGF23 regulates renal sodium handling and blood pressure. EMBO Mol Med, 2014; 6: 744-759<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/emmm.201303716</pub-id><pub-id pub-id-type="pmcid">PMC4203353</pub-id><pub-id pub-id-type="pmid">24797667</pub-id></mixed-citation></ref><ref id="X96"><label>95)</label><mixed-citation publication-type="journal">Weber KT and Brilla CG: Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation, 1991; 83: 1849-1865<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.cir.83.6.1849</pub-id><pub-id pub-id-type="pmid">1828192</pub-id></mixed-citation></ref><ref id="X97"><label>96)</label><mixed-citation publication-type="journal">Dahl&#246;f B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, and Wedel H: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 2002; 359: 995-1003<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(02)08089-3</pub-id><pub-id pub-id-type="pmid">11937178</pub-id></mixed-citation></ref><ref id="X98"><label>97)</label><mixed-citation publication-type="journal">Vaidya A and Williams JS: The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes. Metabolism, 2012; 61: 450-458<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.metabol.2011.09.007</pub-id><pub-id pub-id-type="pmcid">PMC3290690</pub-id><pub-id pub-id-type="pmid">22075270</pub-id></mixed-citation></ref><ref id="X99"><label>98)</label><mixed-citation publication-type="journal">Dai B, David V, Martin A, Huang J, Li H, Jiao Y, Gu W, and Quarles LD: A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One, 2012; 7: e44161<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0044161</pub-id><pub-id pub-id-type="pmcid">PMC3435395</pub-id><pub-id pub-id-type="pmid">22970174</pub-id></mixed-citation></ref><ref id="X100"><label>99)</label><mixed-citation publication-type="journal">Giachelli CM: Vascular calcification mechanisms. Am Soc Nephrol, 2004; 15: 2959-2964<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.ASN.0000145894.57533.C4</pub-id><pub-id pub-id-type="pmid">15579497</pub-id></mixed-citation></ref><ref id="X101"><label>100)</label><mixed-citation publication-type="journal">Polonsky TS, McClelland RL, Jorgensen NW, Bild DE, Burke GL, Guerci AD, and Greenland P: Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA, 2010; 303: 1610-1616<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2010.461</pub-id><pub-id pub-id-type="pmcid">PMC3033741</pub-id><pub-id pub-id-type="pmid">20424251</pub-id></mixed-citation></ref><ref id="X102"><label>101)</label><mixed-citation publication-type="journal">Hecht HS: Coronary artery calcium scanning: past, present, and future. JACC Cardiovasc Imaging, 2015; 8: 579-596<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcmg.2015.02.006</pub-id><pub-id pub-id-type="pmid">25937196</pub-id></mixed-citation></ref><ref id="X103"><label>102)</label><mixed-citation publication-type="journal">Morita H, Takeda Y, Fujita S, Okamoto Y, Sakane K, Teramoto K, Ozeki M, Tasaki R, Kizawa S, Sohmiya K, Hoshiga M, and Ishizaka N: Gender specific association between serum fibroblast growth factor 23/&#945;-klotho and coronary artery and aortic valve calcification. J Atheroscler Thromb, 2015; 22: 1338-1346<pub-id pub-id-type="doi" assigning-authority="pmc">10.5551/jat.30635</pub-id><pub-id pub-id-type="pmid">26279337</pub-id></mixed-citation></ref><ref id="X104"><label>103)</label><mixed-citation publication-type="journal">Yamada S and Giachelli CM: Vascular calcification in CKD-MBD: Roles for phosphate, FGF23, and klotho. Bone, 2017; 100: 87-93<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bone.2016.11.012</pub-id><pub-id pub-id-type="pmcid">PMC5429216</pub-id><pub-id pub-id-type="pmid">27847254</pub-id></mixed-citation></ref><ref id="X105"><label>104)</label><mixed-citation publication-type="journal">Heiss A, DuChesne A, Denecke B, Gr&#246;tzinger J, Yamamoto K, Renn&#233; T, and Jahnen-Dechent W: Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A: formation of colloidal calciprotein particles. J Biol Chem, 2003; 278: 13333-13341<pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M210868200</pub-id><pub-id pub-id-type="pmid">12556469</pub-id></mixed-citation></ref><ref id="X106"><label>105)</label><mixed-citation publication-type="journal">Kutikhin AG, Feenstra L, Kostyunin AE, Yuzhalin AE, Hillebrands JL, and Krenning G: Calciprotein particles: balancing mineral homeostasis and vascular pathology. Arterioscler Thromb Vasc Biol, 2021; 41: 1607-1624<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/ATVBAHA.120.315697</pub-id><pub-id pub-id-type="pmcid">PMC8057528</pub-id><pub-id pub-id-type="pmid">33691479</pub-id></mixed-citation></ref><ref id="X107"><label>106)</label><mixed-citation publication-type="journal">Akiyama KI, Miura Y, Hayashi H, Sakata A, Matsumura Y, Kojima M, Tsuchiya K, Nitta K, Shiizaki K, Kurosu H, and Kuro-o M: Calciprotein particles regulate fibroblast growth factor-23 expression in osteoblasts. Kidney Int, 2020; 97: 702-712<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.kint.2019.10.019</pub-id><pub-id pub-id-type="pmid">32001068</pub-id></mixed-citation></ref><ref id="X108"><label>107)</label><mixed-citation publication-type="journal">Hamano T, Matsui I, Mikami S, Tomida K, Fujii N, Imai E, Rakugi H, and Isaka Y: Fetuin-mineral complex reflects extraosseous calcification stress in CKD. J Am Soc Nephrol, 2010; 21: 1998-2007<pub-id pub-id-type="doi" assigning-authority="pmc">10.1681/ASN.2009090944</pub-id><pub-id pub-id-type="pmcid">PMC3014014</pub-id><pub-id pub-id-type="pmid">20947626</pub-id></mixed-citation></ref><ref id="X109"><label>108)</label><mixed-citation publication-type="journal">Chen W, Fitzpatrick J, Monroy-Trujillo JM, Sozio SM, Jaar BG, Estrella MM, Serrano J, Anokhina V, Miller BL, Melamed ML, Bushinsky DA, and Parekh RS: Associations of serum calciprotein particle size and transformation time with arterial calcification, arterial stiffness, and mortality in incident hemodialysis patients. Am J Kidney Dis, 2021; 77: 346-354<pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.ajkd.2020.05.031</pub-id><pub-id pub-id-type="pmcid">PMC7881044</pub-id><pub-id pub-id-type="pmid">32800846</pub-id></mixed-citation></ref><ref id="X110"><label>109)</label><mixed-citation publication-type="journal">Aghagolzadeh P, Bachtler M, Bijarnia R, Jackson C, Smith ER, Odermatt A, Radpour R, Pasch A: Calcification of vascular smooth muscle cells is induced by secondary calciprotein particles and enhanced by tumor necrosis factor-&#945;. Atherosclerosis, 2016; 251: 404-414<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.atherosclerosis.2016.05.044</pub-id><pub-id pub-id-type="pmid">27289275</pub-id></mixed-citation></ref><ref id="X111"><label>110)</label><mixed-citation publication-type="journal">J&#228;ger E, Murthy S, Schmidt C, Hahn M, Strobel S, Peters A, St&#228;ubert C, Sungur P, Venus T, Geisler M, Radusheva V, Raps S, Rothe K, Scholz R, Jung S, Wagner S, Pierer M, Seifert O, Chang W, Estrela-Lopis I, Raulien N, Krohn K, Str&#228;ter N, Hoeppener S, Sch&#246;neberg T, Rossol M, and Wagner U: Calcium-sensing receptor-mediated NLRP3 inflammasome response to calciprotein particles drives inflammation in rheumatoid arthritis. Nat Commun, 2020; 11: 4243<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-17749-6</pub-id><pub-id pub-id-type="pmcid">PMC7447633</pub-id><pub-id pub-id-type="pmid">32843625</pub-id></mixed-citation></ref><ref id="X112"><label>111)</label><mixed-citation publication-type="journal">Smith JG, Luk K, Schulz CA, Engert JC, Do R, Hindy G, Rukh G, Dufresne L, Almgren P, Owens DS, Harris TB, Peloso GM, Kerr KF, Wong Q, Smith AV, Budoff MJ, Rotter JI, Cupples LA, Rich S, Kathiresan S, Orho-Melander M, Gudnason V, O&#8217;Donnell CJ, Post WS, and Thanassoulis G: Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. JAMA, 2014; 312: 1764-1771<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2014.13959</pub-id><pub-id pub-id-type="pmcid">PMC4280258</pub-id><pub-id pub-id-type="pmid">25344734</pub-id></mixed-citation></ref><ref id="X113"><label>112)</label><mixed-citation publication-type="journal">Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, Kerr KF, Pechlivanis S, Budoff MJ, Harris TB, Malhotra R, O&#8217;Brien KD, Kamstrup PR, Nordestgaard BG, Tybjaerg-Hansen A, Allison MA, Aspelund T, Criqui MH, Heckbert SR, Hwang SJ, Liu Y, Sjogren M, van der Pals J, K&#228;lsch H, M&#252;hleisen TW, N&#246;then MM, Cupples LA, Caslake M, Di Angelantonio E, Danesh J, Rotter JI, Sigurdsson S, Wong Q, Erbel R, Kathiresan S, Melander O, Gudnason V, O&#8217;Donnell CJ, and Post WS: Genetic associations with valvular calcification and aortic stenosis. N Engl J Med, 2013; 368: 503-512<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1109034</pub-id><pub-id pub-id-type="pmcid">PMC3766627</pub-id><pub-id pub-id-type="pmid">23388002</pub-id></mixed-citation></ref><ref id="X114"><label>113)</label><mixed-citation publication-type="journal">Zhao Y, Nicoll R, He YH, and Henein MY: The effect of statins on valve function and calcification in aortic stenosis: a meta-analysis. Atherosclerosis, 2016; 246: 318-324<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.atherosclerosis.2016.01.023</pub-id><pub-id pub-id-type="pmid">26828749</pub-id></mixed-citation></ref><ref id="X115"><label>114)</label><mixed-citation publication-type="journal">Linefsky JP, O&#8217;Brien KD, Sachs M, Katz R, Eng J, Michos ED, Budoff MJ, de Boer I, and Kestenbaum B: Serum phosphate is associated with aortic valve calcification in the Multi-ethnic Study of Atherosclerosis (MESA). Atherosclerosis, 2014; 233: 331-337<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.atherosclerosis.2013.12.051</pub-id><pub-id pub-id-type="pmcid">PMC3992246</pub-id><pub-id pub-id-type="pmid">24530958</pub-id></mixed-citation></ref><ref id="X116"><label>115)</label><mixed-citation publication-type="journal">Cheek JD, Wirrig EE, Alfieri CM, James JF, and Yutzey KE: Differential activation of valvulogenic, chondrogenic, and osteogenic pathways in mouse models of myxomatous and calcific aortic valve disease. J Mol Cell Cardiol, 2012; 52: 689-700<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.yjmcc.2011.12.013</pub-id><pub-id pub-id-type="pmcid">PMC3294059</pub-id><pub-id pub-id-type="pmid">22248532</pub-id></mixed-citation></ref><ref id="X117"><label>116)</label><mixed-citation publication-type="journal">Wirrig EE, Hinton RB, and Yutzey KE: Differential expression of cartilage and bone-related proteins in pediatric and adult diseased aortic valves. J Mol Cell Cardiol, 2011; 50: 561-569<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.yjmcc.2010.12.005</pub-id><pub-id pub-id-type="pmcid">PMC3035730</pub-id><pub-id pub-id-type="pmid">21163264</pub-id></mixed-citation></ref><ref id="X118"><label>117)</label><mixed-citation publication-type="journal">Gomez-Stallons MV, Wirrig-Schwendeman EE, Hassel KR, Conway SJ, and Yutzey KE: Bone morphogenetic protein signaling is required for aortic valve calcification. Arterioscler Thromb Vasc Biol, 2016; 36: 1398-1405<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/ATVBAHA.116.307526</pub-id><pub-id pub-id-type="pmcid">PMC4919184</pub-id><pub-id pub-id-type="pmid">27199449</pub-id></mixed-citation></ref><ref id="X119"><label>118)</label><mixed-citation publication-type="journal">Vidula MK, Orlenko A, Zhao L, Salvador L, Small AM, Horton E, Cohen JB, Adusumalli S, Denduluri S, Kobayashi T, Hyman M, Fiorilli P, Magro C, Singh B, Pourmussa B, Greczylo C, Basso M, Ebert C, Yarde M, Li Z, Cvijic ME, Wang Z, Walsh A, Maranville J, Kick E, Luettgen J, Adam L, Schafer P, Ramirez-Valle F, Seiffert D, Moore JH, Gordon D, and Chirinos JA: Plasma biomarkers associated with adverse outcomes in patients with calcific aortic stenosis. Eur J Heart Fail, 2021; 23: 2021-2032<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ejhf.2361</pub-id><pub-id pub-id-type="pmid">34632675</pub-id></mixed-citation></ref><ref id="X120"><label>119)</label><mixed-citation publication-type="journal">Yu X, Ibrahimi OA, Goetz R, Zhang F, Davis SI, Garringer HJ, Linhardt RJ, Ornitz DM, Mohammadi M, and White KE: Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology, 2005; 146: 4647-4656<pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/en.2005-0670</pub-id><pub-id pub-id-type="pmcid">PMC4140631</pub-id><pub-id pub-id-type="pmid">16081635</pub-id></mixed-citation></ref><ref id="X121"><label>120)</label><mixed-citation publication-type="journal">Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, and Singer DE: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA, 2001; 285: 2370-2375<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.285.18.2370</pub-id><pub-id pub-id-type="pmid">11343485</pub-id></mixed-citation></ref><ref id="X122"><label>121)</label><mixed-citation publication-type="journal">Mathew JS, Sachs MC, Katz R, Patton KK, Heckbert SR, Hoofnagle AN, Alonso A, Chonchol M, Deo R, Ix JH, Siscovick DS, Kestenbaum B, and de Boer IH: Fibroblast growth factor-23 and incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS). Circulation, 2014; 130: 298-307<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.113.005499</pub-id><pub-id pub-id-type="pmcid">PMC4108550</pub-id><pub-id pub-id-type="pmid">24920722</pub-id></mixed-citation></ref><ref id="X123"><label>122)</label><mixed-citation publication-type="journal">Mehta R, Cai X, Lee J, Scialla JJ, Bansal N, Sondheimer JH, Chen J, Hamm LL, Ricardo AC, Navaneethan SD, Deo R, Rahman M, Feldman HI, Go AS, Isakova T, and Wolf M: Association of fibroblast growth factor 23 with atrial fibrillation in chronic kidney disease, from the chronic renal insufficiency cohort study. JAMA Cardio, 2016; 1: 548-556<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamacardio.2016.1445</pub-id><pub-id pub-id-type="pmcid">PMC4992989</pub-id><pub-id pub-id-type="pmid">27434583</pub-id></mixed-citation></ref><ref id="X124"><label>123)</label><mixed-citation publication-type="journal">Alonso A, Misialek JR, Eckfeldt JH, Selvin E, Coresh J, Chen LY, Soliman EZ, Agarwal SK, and Lutsey PL: Circulating fibroblast growth factor-23 and the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities study. J Am Heart Assoc, 2014; 3: e001082<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/JAHA.114.001082</pub-id><pub-id pub-id-type="pmcid">PMC4323781</pub-id><pub-id pub-id-type="pmid">25237047</pub-id></mixed-citation></ref><ref id="X125"><label>124)</label><mixed-citation publication-type="journal">Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Guti&#233;rrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-o M, Kusek JW, Keane MG, and Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest, 2011; 121: 4393-4408<pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI46122</pub-id><pub-id pub-id-type="pmcid">PMC3204831</pub-id><pub-id pub-id-type="pmid">21985788</pub-id></mixed-citation></ref><ref id="X126"><label>125)</label><mixed-citation publication-type="journal">Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, and Yamashita T: FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res, 2004; 19: 429-435<pub-id pub-id-type="doi" assigning-authority="pmc">10.1359/JBMR.0301264</pub-id><pub-id pub-id-type="pmid">15040831</pub-id></mixed-citation></ref><ref id="X127"><label>126)</label><mixed-citation publication-type="journal">D, Kretzler M, Nessel L, Hamm LL, Negrea L, Leonard MB, Raj D, and Wolf M: Fibroblast growth factor 23 and inflammation in CKD. Clin J Am Soc Nephrol, 2012; 7: 1155-1162<pub-id pub-id-type="doi" assigning-authority="pmc">10.2215/CJN.13281211</pub-id><pub-id pub-id-type="pmcid">PMC3386678</pub-id><pub-id pub-id-type="pmid">22554719</pub-id></mixed-citation></ref><ref id="X128"><label>127)</label><mixed-citation publication-type="journal">Mirza MA, Larsson A, Lind L, and Larsson TE: Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis, 2009; 205: 385-390<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.atherosclerosis.2009.01.001</pub-id><pub-id pub-id-type="pmid">19181315</pub-id></mixed-citation></ref><ref id="B128"><label>128)</label><mixed-citation publication-type="journal">Malyszko J, Koc-Zorawska E, Matuszkiewicz-Rowinska J, and Malyszko J: FGF23 and Klotho in relation to markers of endothelial dysfunction in kidney transplant recipients. Transplant Proc, 2014; 46: 2647-2650<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.transproceed.2014.09.015</pub-id><pub-id pub-id-type="pmid">25380886</pub-id></mixed-citation></ref><ref id="X129"><label>129)</label><mixed-citation publication-type="journal">Natsuki Y, Morioka T, Kakutani Y, Yamazaki Y, Ochi A, Kurajoh M, Mori K, Imanishi Y, Shoji T, Inaba M, and Emoto M: Serum fibroblast growth factor 23 levels are associated with vascular smooth muscle dysfunction in type 2 diabetes. J Atheroscler Thromb, 2023; 30: 1838-1848<pub-id pub-id-type="doi" assigning-authority="pmc">10.5551/jat.64000</pub-id><pub-id pub-id-type="pmcid">PMC10703563</pub-id><pub-id pub-id-type="pmid">37225519</pub-id></mixed-citation></ref><ref id="X130"><label>130)</label><mixed-citation publication-type="journal">Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, and Solomon SD: Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA, 2012; 307: 674-684<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2012.120</pub-id><pub-id pub-id-type="pmid">22337679</pub-id></mixed-citation></ref><ref id="X131"><label>131)</label><mixed-citation publication-type="journal">Tamez H, Zoccali C, Packham D, Wenger J, Bhan I, Appelbaum E, Pritchett Y, Chang Y, Agarwal R, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Singh B, Zehnder D, Pachika A, Manning WJ, Shah A, Solomon SD, and Thadhani R: Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J, 2012; 164: 902-9.e2<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ahj.2012.09.018</pub-id><pub-id pub-id-type="pmid">23194491</pub-id></mixed-citation></ref><ref id="X132"><label>132)</label><mixed-citation publication-type="journal">Covic A, Kothawala P, Bernal M, Robbins S, Chalian A, and Goldsmith D: Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant, 2009; 24: 1506-1523<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ndt/gfn613</pub-id><pub-id pub-id-type="pmid">19001560</pub-id></mixed-citation></ref><ref id="X133"><label>133)</label><mixed-citation publication-type="journal">Lioufas NM, Pascoe EM, Hawley CM, Elder GJ, Badve SV, Block GA, Johnson DW, and Toussaint ND: Systematic review and meta-analyses of the effects of phosphate-lowering agents in nondialysis CKD. J Am Soc Nephrol, 2022; 33: 59-76<pub-id pub-id-type="doi" assigning-authority="pmc">10.1681/ASN.2021040554</pub-id><pub-id pub-id-type="pmcid">PMC8763193</pub-id><pub-id pub-id-type="pmid">34645696</pub-id></mixed-citation></ref><ref id="X134"><label>134)</label><mixed-citation publication-type="journal">Isaka Y, Hamano T, Fujii H, Tsujimoto Y, Koiwa F, Sakaguchi Y, Tanaka R, Tomiyama N, Tatsugami F, and Teramukai S: Optimal phosphate control related to coronary artery calcification in dialysis patients. J Am Soc Nephrol, 202; 32: 723-735<pub-id pub-id-type="doi" assigning-authority="pmc">10.1681/ASN.2020050598</pub-id><pub-id pub-id-type="pmcid">PMC7920180</pub-id><pub-id pub-id-type="pmid">33547218</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>